[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ftV6MKuzq-vQLJb7OwV6C40SkWmfxlxBI5ZBmRagAsL8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":87,"rows":94},"Canadian Cancer Trials Group",[4],92,false,54,21,27584,87,20,[14,17,20,23,26,29,31,34],{"name":15,"count":16},"Breast Cancer",9,{"name":18,"count":19},"Prostate Cancer",7,{"name":21,"count":22},"Cancer",5,{"name":24,"count":25},"Colorectal Cancer",4,{"name":27,"count":28},"Chronic Lymphocytic Leukemia",3,{"name":30,"count":28},"Multiple Myeloma",{"name":32,"count":33},"Melanoma",2,{"name":35,"count":33},"Brain Metastases",[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT01396408","A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours","2015-07-06","Sunitinib",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT02537418","Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens","2018-07-20","durvalumab",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT02285816","MG1 Maraba\u002FMAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours","2019-09-19","MG1MA3",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT03057106","Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC","2020-02-24","Durvalumab",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT02905318","Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer","2022-04-29","Palbociclib",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT04176848","CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer","2022-09-15","CFI-400945",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT03568422","CFI-402257 in Combination With Paclitaxel in Patients With Advanced\u002FMetastatic HER2-Negative Breast Cancer","2022-11-21","CFI-402257",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT03822897","De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma","2024-06-25","Cisplatin",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT03385655","Prostate Cancer Biomarker Enrichment and Treatment Selection","2024-10-07","Adavosertib",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT04650581","Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4\u002F6 Inhibitor and Aromatase Inhibitor","2025-05-23","Ipatasertib",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,195,263,322,388,410,435,467,495,521,539,564,582,600,618,646,664,682,700,726,744,762,780,798,822,965,1023,1070,1120,1154,1187,1249,1286,1343,1365,1387,1412,1434,1456,1478,1496,1514,1532,1550,1568,1590,1608,1626,1644,1668,1686,1711,1729,1747,1765,1783,1801,1819,1837,1855,1873,1891,1909,1927,1945,1963,1981,1999,2017,2035,2053,2071,2089,2107,2125,2143,2168,2186,2204,2222,2240,2265,2283,2301,2319,2337,2355,2373,2403,2428,2454,2481,2499,2524,2546,2568,2590,2614,2632,2650,2676,2694,2720,2738,2756,2774,2792,2810,2836,2854,2879,2897,2915,2941,2959,2984,3002,3020,3045,3063,3088,3106,3130],{"intervention":96,"totalTrials":97,"cells":98},"Dexamethasone",6,{"EARLY_PHASE1":99,"PHASE1":119,"PHASE2":135,"PHASE3":176,"PHASE4":191,"NA":193},{"trials":100,"activeCount":118,"soonestReadout":106},[101],{"nctId":102,"briefTitle":103,"status":104,"phases":105,"primaryCompletion":106,"completion":106,"start":107,"enrollment":108,"conditions":109,"interventions":111},"NCT04161248","Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma","ACTIVE_NOT_RECRUITING",[88],"2026-12-31","2020-09-02",40,[110],"Lymphoma, B-Cell",[112,113,114,115,96,76,116,117],"Venetoclax","Rituximab","Rituximab SC","Gemcitabine","Glofitamab","Tafasitamab",1,{"trials":120,"activeCount":134},[121],{"nctId":122,"briefTitle":123,"status":124,"phases":125,"primaryCompletion":126,"completion":127,"start":128,"enrollment":9,"conditions":129,"interventions":132},"NCT01846390","Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma","COMPLETED",[89],"2016-07-06","2018-09-19","2013-10-01",[130,131],"Peripheral T-Cell Lymphoma","Diffuse Large B-Cell Lymphoma",[115,96,76,133],"Romidepsin",0,{"trials":136,"activeCount":33,"soonestReadout":141},[137,153,165],{"nctId":138,"briefTitle":139,"status":104,"phases":140,"primaryCompletion":141,"completion":106,"start":142,"enrollment":143,"conditions":144,"interventions":146},"NCT02436707","Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma",[90],"2026-06-30","2015-10-27",129,[145],"Lymphoma",[147,113,115,96,76,148,149,150,151,152],"Ibrutinib","Mesna","Cyclophosphamide","Etoposide","G-CSF","Selinexor",{"nctId":154,"briefTitle":155,"status":156,"phases":157,"primaryCompletion":106,"completion":106,"start":158,"enrollment":159,"conditions":160,"interventions":162},"NCT05180097","Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed\u002FRefractory Hodgkin Lymphoma","RECRUITING",[90],"2022-11-01",84,[161],"Hodgkin Lymphoma",[115,96,76,163,164],"Brentuximab vedotin","Pembrolizumab",{"nctId":166,"briefTitle":167,"status":124,"phases":168,"primaryCompletion":169,"completion":170,"start":171,"enrollment":172,"conditions":173,"interventions":174},"NCT02597062","High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma",[90],"2019-06-19","2022-02-01","2016-07-05",76,[30],[175,149,96],"Carfilzomib",{"trials":177,"activeCount":118,"soonestReadout":182},[178],{"nctId":179,"briefTitle":180,"status":156,"phases":181,"primaryCompletion":182,"completion":183,"start":184,"enrollment":185,"conditions":186,"interventions":187},"NCT06182774","Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma",[91],"2032-01-31","2032-07-31","2024-04-10",570,[30],[188,189,96,190],"Daratumumab","Lenalidomide","Isatuximab",{"trials":192,"activeCount":134},[],{"trials":194,"activeCount":134},[],{"intervention":196,"totalTrials":25,"cells":197},"Docetaxel",{"EARLY_PHASE1":198,"PHASE1":200,"PHASE2":202,"PHASE3":228,"PHASE4":259,"NA":261},{"trials":199,"activeCount":134},[],{"trials":201,"activeCount":134},[],{"trials":203,"activeCount":118,"soonestReadout":222},[204,218],{"nctId":205,"briefTitle":206,"status":124,"phases":207,"primaryCompletion":208,"completion":209,"start":210,"enrollment":211,"conditions":212,"interventions":214},"NCT01708993","Reolysin in Previously Treated Advanced\u002FMetastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy",[90],"2016-01-26","2018-09-26","2012-12-10",166,[213],"Non Small Cell Lung Cancer",[215,216,217,196],"Pemetrexed and Reolysin","Pemetrexed","Docetaxel and Reolysin",{"nctId":219,"briefTitle":220,"status":104,"phases":221,"primaryCompletion":222,"completion":106,"start":223,"enrollment":224,"conditions":225,"interventions":226},"NCT04663997","177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer",[90],"2025-08-25","2021-08-11",200,[18],[227,196],"177Lu-PSMA-617",{"trials":229,"activeCount":33,"soonestReadout":234},[230,243],{"nctId":231,"briefTitle":232,"status":156,"phases":233,"primaryCompletion":234,"completion":235,"start":236,"enrollment":237,"conditions":238,"interventions":241},"NCT06439225","Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes",[91],"2029-09-30","2030-03-31","2024-12-30",236,[239,240],"Metastatic Castration-resistant Prostate Cancer","Metastatic Prostate Cancer",[196,242],"Carboplatin",{"nctId":244,"briefTitle":245,"status":156,"phases":246,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":251,"interventions":253},"NCT06592924","Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response",[91],"2031-03-14","2031-04-15","2025-05-28",830,[252],"Prostate Cancer (Adenocarcinoma)",[254,255,256,257,196,258],"Abiraterone","Enzalutamide","Apalutamide","Darolutamide","ADT",{"trials":260,"activeCount":134},[],{"trials":262,"activeCount":134},[],{"intervention":164,"totalTrials":22,"cells":264},{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":296,"PHASE4":318,"NA":320},{"trials":266,"activeCount":134},[],{"trials":268,"activeCount":134},[],{"trials":270,"activeCount":118,"soonestReadout":106},[271,282,286],{"nctId":272,"briefTitle":273,"status":274,"phases":275,"primaryCompletion":276,"completion":277,"start":278,"enrollment":16,"conditions":279,"interventions":281},"NCT02740920","Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker","TERMINATED",[90],"2019-03-22","2019-09-30","2017-01-10",[280],"Metastatic Melanoma",[164],{"nctId":154,"briefTitle":155,"status":156,"phases":283,"primaryCompletion":106,"completion":106,"start":158,"enrollment":159,"conditions":284,"interventions":285},[90],[161],[115,96,76,163,164],{"nctId":287,"briefTitle":288,"status":289,"phases":290,"primaryCompletion":291,"completion":291,"start":291,"enrollment":134,"conditions":292,"interventions":294},"NCT05743777","PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma","WITHDRAWN",[90],"2023-05-12",[293],"Advanced Head and Neck Squamous Cell Carcinoma",[164,295],"MET-4",{"trials":297,"activeCount":118,"soonestReadout":106},[298,308],{"nctId":299,"briefTitle":300,"status":156,"phases":301,"primaryCompletion":106,"completion":302,"start":303,"enrollment":304,"conditions":305,"interventions":307},"NCT04093167","Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer",[90,91],"2027-07-30","2020-05-26",230,[306],"Lung Cancer",[164],{"nctId":309,"briefTitle":310,"status":124,"phases":311,"primaryCompletion":312,"completion":312,"start":313,"enrollment":314,"conditions":315,"interventions":317},"NCT02784171","Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma",[90,91],"2024-10-11","2016-11-11",520,[316],"Mesothelioma",[76,216,164],{"trials":319,"activeCount":134},[],{"trials":321,"activeCount":134},[],{"intervention":242,"totalTrials":22,"cells":323},{"EARLY_PHASE1":324,"PHASE1":326,"PHASE2":340,"PHASE3":378,"PHASE4":384,"NA":386},{"trials":325,"activeCount":134},[],{"trials":327,"activeCount":134},[328],{"nctId":329,"briefTitle":330,"status":124,"phases":331,"primaryCompletion":332,"completion":333,"start":334,"enrollment":335,"conditions":336,"interventions":337},"NCT01783197","Study of Selumetinib in Patients With Previously Treated or Untreated Advanced\u002FMetastatic NSCLC",[89],"2017-04-18","2019-04-02","2013-06-04",39,[213],[338,242,339,216,76],"Paclitaxel","Selumetinib",{"trials":341,"activeCount":118,"soonestReadout":80},[342,350,367],{"nctId":78,"briefTitle":79,"status":104,"phases":343,"primaryCompletion":80,"completion":344,"start":345,"enrollment":224,"conditions":346,"interventions":347},[90],"2025-12-31","2018-08-01",[18],[81,348,257,66,86,349,242],"Savolitinib","Durvalumab and Tremelimumab",{"nctId":351,"briefTitle":352,"status":124,"phases":353,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":363},"NCT00993655","Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer",[90],"2016-03-10","2016-07-11","2010-03-03",275,[359,360,361,362],"Fallopian Tube Cancer","Metastatic Cancer","Ovarian Cancer","Peritoneal Cavity Cancer",[364,365,366],"carboplatin","cisplatin","paclitaxel",{"nctId":368,"briefTitle":369,"status":124,"phases":370,"primaryCompletion":371,"completion":372,"start":373,"enrollment":374,"conditions":375,"interventions":377},"NCT02337530","Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC",[90],"2017-10-31","2019-06-18","2015-05-26",62,[376],"Non-Small Cell Lung Cancer",[339,216,76,242],{"trials":379,"activeCount":118,"soonestReadout":234},[380],{"nctId":231,"briefTitle":232,"status":156,"phases":381,"primaryCompletion":234,"completion":235,"start":236,"enrollment":237,"conditions":382,"interventions":383},[91],[239,240],[196,242],{"trials":385,"activeCount":134},[],{"trials":387,"activeCount":134},[],{"intervention":257,"totalTrials":33,"cells":389},{"EARLY_PHASE1":390,"PHASE1":392,"PHASE2":394,"PHASE3":400,"PHASE4":406,"NA":408},{"trials":391,"activeCount":134},[],{"trials":393,"activeCount":134},[],{"trials":395,"activeCount":118,"soonestReadout":80},[396],{"nctId":78,"briefTitle":79,"status":104,"phases":397,"primaryCompletion":80,"completion":344,"start":345,"enrollment":224,"conditions":398,"interventions":399},[90],[18],[81,348,257,66,86,349,242],{"trials":401,"activeCount":118,"soonestReadout":247},[402],{"nctId":244,"briefTitle":245,"status":156,"phases":403,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":404,"interventions":405},[91],[252],[254,255,256,257,196,258],{"trials":407,"activeCount":134},[],{"trials":409,"activeCount":134},[],{"intervention":86,"totalTrials":33,"cells":411},{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":416,"PHASE3":422,"PHASE4":431,"NA":433},{"trials":413,"activeCount":134},[],{"trials":415,"activeCount":134},[],{"trials":417,"activeCount":118,"soonestReadout":80},[418],{"nctId":78,"briefTitle":79,"status":104,"phases":419,"primaryCompletion":80,"completion":344,"start":345,"enrollment":224,"conditions":420,"interventions":421},[90],[18],[81,348,257,66,86,349,242],{"trials":423,"activeCount":118,"soonestReadout":85},[424],{"nctId":83,"briefTitle":84,"status":104,"phases":425,"primaryCompletion":85,"completion":106,"start":426,"enrollment":427,"conditions":428,"interventions":429},[91],"2021-01-27",250,[15],[86,430],"Fulvestrant",{"trials":432,"activeCount":134},[],{"trials":434,"activeCount":134},[],{"intervention":430,"totalTrials":33,"cells":436},{"EARLY_PHASE1":437,"PHASE1":439,"PHASE2":441,"PHASE3":457,"PHASE4":463,"NA":465},{"trials":438,"activeCount":134},[],{"trials":440,"activeCount":134},[],{"trials":442,"activeCount":118,"soonestReadout":447},[443],{"nctId":444,"briefTitle":445,"status":156,"phases":446,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":451,"interventions":452},"NCT05601440","Liquid-biopsy Informed Platform Trial to Evaluate CDK4\u002F6-inhibitor Resistant ER+\u002FHER2- Metastatic Breast Cancer",[90],"2027-12-31","2028-06-30","2023-06-13",484,[15],[453,115,454,430,455,71,66,456],"RP-6306","Niraparib","RP-3500","Sacituzumab govitecan",{"trials":458,"activeCount":118,"soonestReadout":85},[459],{"nctId":83,"briefTitle":84,"status":104,"phases":460,"primaryCompletion":85,"completion":106,"start":426,"enrollment":427,"conditions":461,"interventions":462},[91],[15],[86,430],{"trials":464,"activeCount":134},[],{"trials":466,"activeCount":134},[],{"intervention":258,"totalTrials":33,"cells":468},{"EARLY_PHASE1":469,"PHASE1":471,"PHASE2":473,"PHASE3":475,"PHASE4":491,"NA":493},{"trials":470,"activeCount":134},[],{"trials":472,"activeCount":134},[],{"trials":474,"activeCount":134},[],{"trials":476,"activeCount":33,"soonestReadout":247},[477,481],{"nctId":244,"briefTitle":245,"status":156,"phases":478,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":479,"interventions":480},[91],[252],[254,255,256,257,196,258],{"nctId":482,"briefTitle":483,"status":156,"phases":484,"primaryCompletion":485,"completion":486,"start":487,"enrollment":488,"conditions":489,"interventions":490},"NCT06235697","Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment",[91],"2032-10-31","2033-04-30","2024-04-25",710,[18],[258],{"trials":492,"activeCount":134},[],{"trials":494,"activeCount":134},[],{"intervention":496,"totalTrials":118,"cells":497},"Intermittent PD-1 inhibitor therapy",{"EARLY_PHASE1":498,"PHASE1":500,"PHASE2":502,"PHASE3":504,"PHASE4":517,"NA":519},{"trials":499,"activeCount":134},[],{"trials":501,"activeCount":134},[],{"trials":503,"activeCount":134},[],{"trials":505,"activeCount":118,"soonestReadout":447},[506],{"nctId":507,"briefTitle":508,"status":156,"phases":509,"primaryCompletion":447,"completion":510,"start":511,"enrollment":512,"conditions":513,"interventions":515},"NCT02821013","Duration of Anti-PD-1 Therapy in Metastatic Melanoma",[91],"2029-12-31","2016-10-31",614,[514],"Unresectable\u002FMetastatic Melanoma",[496,516],"Continuous PD-1 inhibitor therapy",{"trials":518,"activeCount":134},[],{"trials":520,"activeCount":134},[],{"intervention":516,"totalTrials":118,"cells":522},{"EARLY_PHASE1":523,"PHASE1":525,"PHASE2":527,"PHASE3":529,"PHASE4":535,"NA":537},{"trials":524,"activeCount":134},[],{"trials":526,"activeCount":134},[],{"trials":528,"activeCount":134},[],{"trials":530,"activeCount":118,"soonestReadout":447},[531],{"nctId":507,"briefTitle":508,"status":156,"phases":532,"primaryCompletion":447,"completion":510,"start":511,"enrollment":512,"conditions":533,"interventions":534},[91],[514],[496,516],{"trials":536,"activeCount":134},[],{"trials":538,"activeCount":134},[],{"intervention":540,"totalTrials":118,"cells":541},"MEDI4736",{"EARLY_PHASE1":542,"PHASE1":544,"PHASE2":546,"PHASE3":548,"PHASE4":560,"NA":562},{"trials":543,"activeCount":134},[],{"trials":545,"activeCount":134},[],{"trials":547,"activeCount":134},[],{"trials":549,"activeCount":118,"soonestReadout":554},[550],{"nctId":551,"briefTitle":552,"status":104,"phases":553,"primaryCompletion":554,"completion":555,"start":556,"enrollment":557,"conditions":558,"interventions":559},"NCT02273375","Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC",[91],"2025-07-23","2026-01-31","2015-02-24",1415,[376],[540],{"trials":561,"activeCount":134},[],{"trials":563,"activeCount":134},[],{"intervention":188,"totalTrials":118,"cells":565},{"EARLY_PHASE1":566,"PHASE1":568,"PHASE2":570,"PHASE3":572,"PHASE4":578,"NA":580},{"trials":567,"activeCount":134},[],{"trials":569,"activeCount":134},[],{"trials":571,"activeCount":134},[],{"trials":573,"activeCount":118,"soonestReadout":182},[574],{"nctId":179,"briefTitle":180,"status":156,"phases":575,"primaryCompletion":182,"completion":183,"start":184,"enrollment":185,"conditions":576,"interventions":577},[91],[30],[188,189,96,190],{"trials":579,"activeCount":134},[],{"trials":581,"activeCount":134},[],{"intervention":189,"totalTrials":118,"cells":583},{"EARLY_PHASE1":584,"PHASE1":586,"PHASE2":588,"PHASE3":590,"PHASE4":596,"NA":598},{"trials":585,"activeCount":134},[],{"trials":587,"activeCount":134},[],{"trials":589,"activeCount":134},[],{"trials":591,"activeCount":118,"soonestReadout":182},[592],{"nctId":179,"briefTitle":180,"status":156,"phases":593,"primaryCompletion":182,"completion":183,"start":184,"enrollment":185,"conditions":594,"interventions":595},[91],[30],[188,189,96,190],{"trials":597,"activeCount":134},[],{"trials":599,"activeCount":134},[],{"intervention":190,"totalTrials":118,"cells":601},{"EARLY_PHASE1":602,"PHASE1":604,"PHASE2":606,"PHASE3":608,"PHASE4":614,"NA":616},{"trials":603,"activeCount":134},[],{"trials":605,"activeCount":134},[],{"trials":607,"activeCount":134},[],{"trials":609,"activeCount":118,"soonestReadout":182},[610],{"nctId":179,"briefTitle":180,"status":156,"phases":611,"primaryCompletion":182,"completion":183,"start":184,"enrollment":185,"conditions":612,"interventions":613},[91],[30],[188,189,96,190],{"trials":615,"activeCount":134},[],{"trials":617,"activeCount":134},[],{"intervention":619,"totalTrials":118,"cells":620},"Leucovorin",{"EARLY_PHASE1":621,"PHASE1":623,"PHASE2":625,"PHASE3":627,"PHASE4":642,"NA":644},{"trials":622,"activeCount":134},[],{"trials":624,"activeCount":134},[],{"trials":626,"activeCount":134},[],{"trials":628,"activeCount":118,"soonestReadout":633},[629],{"nctId":630,"briefTitle":631,"status":156,"phases":632,"primaryCompletion":633,"completion":634,"start":635,"enrollment":427,"conditions":636,"interventions":638},"NCT06205485","Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer",[91],"2030-01-30","2030-06-30","2024-06-26",[637],"Rectal Cancer",[619,639,640,641],"Oxaliplatin","Fluoruracil","Capecitabine",{"trials":643,"activeCount":134},[],{"trials":645,"activeCount":134},[],{"intervention":639,"totalTrials":118,"cells":647},{"EARLY_PHASE1":648,"PHASE1":650,"PHASE2":652,"PHASE3":654,"PHASE4":660,"NA":662},{"trials":649,"activeCount":134},[],{"trials":651,"activeCount":134},[],{"trials":653,"activeCount":134},[],{"trials":655,"activeCount":118,"soonestReadout":633},[656],{"nctId":630,"briefTitle":631,"status":156,"phases":657,"primaryCompletion":633,"completion":634,"start":635,"enrollment":427,"conditions":658,"interventions":659},[91],[637],[619,639,640,641],{"trials":661,"activeCount":134},[],{"trials":663,"activeCount":134},[],{"intervention":640,"totalTrials":118,"cells":665},{"EARLY_PHASE1":666,"PHASE1":668,"PHASE2":670,"PHASE3":672,"PHASE4":678,"NA":680},{"trials":667,"activeCount":134},[],{"trials":669,"activeCount":134},[],{"trials":671,"activeCount":134},[],{"trials":673,"activeCount":118,"soonestReadout":633},[674],{"nctId":630,"briefTitle":631,"status":156,"phases":675,"primaryCompletion":633,"completion":634,"start":635,"enrollment":427,"conditions":676,"interventions":677},[91],[637],[619,639,640,641],{"trials":679,"activeCount":134},[],{"trials":681,"activeCount":134},[],{"intervention":641,"totalTrials":118,"cells":683},{"EARLY_PHASE1":684,"PHASE1":686,"PHASE2":688,"PHASE3":690,"PHASE4":696,"NA":698},{"trials":685,"activeCount":134},[],{"trials":687,"activeCount":134},[],{"trials":689,"activeCount":134},[],{"trials":691,"activeCount":118,"soonestReadout":633},[692],{"nctId":630,"briefTitle":631,"status":156,"phases":693,"primaryCompletion":633,"completion":634,"start":635,"enrollment":427,"conditions":694,"interventions":695},[91],[637],[619,639,640,641],{"trials":697,"activeCount":134},[],{"trials":699,"activeCount":134},[],{"intervention":701,"totalTrials":118,"cells":702},"Balstilimab",{"EARLY_PHASE1":703,"PHASE1":705,"PHASE2":707,"PHASE3":709,"PHASE4":722,"NA":724},{"trials":704,"activeCount":134},[],{"trials":706,"activeCount":134},[],{"trials":708,"activeCount":134},[],{"trials":710,"activeCount":118,"soonestReadout":715},[711],{"nctId":712,"briefTitle":713,"status":156,"phases":714,"primaryCompletion":715,"completion":716,"start":717,"enrollment":718,"conditions":719,"interventions":720},"NCT07152821","Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma",[91],"2028-12-31","2029-06-30","2026-03-31",834,[24],[701,721],"Botensilimab",{"trials":723,"activeCount":134},[],{"trials":725,"activeCount":134},[],{"intervention":721,"totalTrials":118,"cells":727},{"EARLY_PHASE1":728,"PHASE1":730,"PHASE2":732,"PHASE3":734,"PHASE4":740,"NA":742},{"trials":729,"activeCount":134},[],{"trials":731,"activeCount":134},[],{"trials":733,"activeCount":134},[],{"trials":735,"activeCount":118,"soonestReadout":715},[736],{"nctId":712,"briefTitle":713,"status":156,"phases":737,"primaryCompletion":715,"completion":716,"start":717,"enrollment":718,"conditions":738,"interventions":739},[91],[24],[701,721],{"trials":741,"activeCount":134},[],{"trials":743,"activeCount":134},[],{"intervention":254,"totalTrials":118,"cells":745},{"EARLY_PHASE1":746,"PHASE1":748,"PHASE2":750,"PHASE3":752,"PHASE4":758,"NA":760},{"trials":747,"activeCount":134},[],{"trials":749,"activeCount":134},[],{"trials":751,"activeCount":134},[],{"trials":753,"activeCount":118,"soonestReadout":247},[754],{"nctId":244,"briefTitle":245,"status":156,"phases":755,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":756,"interventions":757},[91],[252],[254,255,256,257,196,258],{"trials":759,"activeCount":134},[],{"trials":761,"activeCount":134},[],{"intervention":255,"totalTrials":118,"cells":763},{"EARLY_PHASE1":764,"PHASE1":766,"PHASE2":768,"PHASE3":770,"PHASE4":776,"NA":778},{"trials":765,"activeCount":134},[],{"trials":767,"activeCount":134},[],{"trials":769,"activeCount":134},[],{"trials":771,"activeCount":118,"soonestReadout":247},[772],{"nctId":244,"briefTitle":245,"status":156,"phases":773,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":774,"interventions":775},[91],[252],[254,255,256,257,196,258],{"trials":777,"activeCount":134},[],{"trials":779,"activeCount":134},[],{"intervention":256,"totalTrials":118,"cells":781},{"EARLY_PHASE1":782,"PHASE1":784,"PHASE2":786,"PHASE3":788,"PHASE4":794,"NA":796},{"trials":783,"activeCount":134},[],{"trials":785,"activeCount":134},[],{"trials":787,"activeCount":134},[],{"trials":789,"activeCount":118,"soonestReadout":247},[790],{"nctId":244,"briefTitle":245,"status":156,"phases":791,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":792,"interventions":793},[91],[252],[254,255,256,257,196,258],{"trials":795,"activeCount":134},[],{"trials":797,"activeCount":134},[],{"intervention":799,"totalTrials":118,"cells":800},"Memantine",{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":805,"PHASE3":807,"PHASE4":818,"NA":820},{"trials":802,"activeCount":134},[],{"trials":804,"activeCount":134},[],{"trials":806,"activeCount":134},[],{"trials":808,"activeCount":118,"soonestReadout":813},[809],{"nctId":810,"briefTitle":811,"status":156,"phases":812,"primaryCompletion":813,"completion":447,"start":814,"enrollment":815,"conditions":816,"interventions":817},"NCT03550391","Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases",[91],"2027-06-30","2018-11-22",206,[35],[799],{"trials":819,"activeCount":134},[],{"trials":821,"activeCount":134},[],{"intervention":56,"totalTrials":823,"cells":824},13,{"EARLY_PHASE1":825,"PHASE1":827,"PHASE2":849,"PHASE3":959,"PHASE4":961,"NA":963},{"trials":826,"activeCount":134},[],{"trials":828,"activeCount":118,"soonestReadout":45},[829,841],{"nctId":830,"briefTitle":831,"status":124,"phases":832,"primaryCompletion":833,"completion":834,"start":835,"enrollment":836,"conditions":837,"interventions":839},"NCT02649686","Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab",[89],"2017-09-25","2019-11-12","2016-05-17",15,[838],"Metastatic Breast Cancer",[56,840],"Trastuzumab",{"nctId":43,"briefTitle":44,"status":104,"phases":842,"primaryCompletion":45,"completion":106,"start":843,"enrollment":844,"conditions":845,"interventions":847},[89],"2015-10-16",153,[846],"Solid Malignancies",[46,848],"tremelimumab",{"trials":850,"activeCount":19,"soonestReadout":55},[851,863,871,880,891,901,913,925,935,940,949],{"nctId":852,"briefTitle":853,"status":156,"phases":854,"primaryCompletion":855,"completion":856,"start":857,"enrollment":858,"conditions":859,"interventions":860},"NCT03847649","A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+\u002F- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies",[90],"2030-04-30","2031-04-30","2020-03-09",60,[21],[56,861,861,862],"Prednisone","Tremelimumab",{"nctId":53,"briefTitle":54,"status":104,"phases":864,"primaryCompletion":55,"completion":141,"start":865,"enrollment":866,"conditions":867,"interventions":869},[90],"2017-03-28",301,[868],"Lung Cancer Metastatic",[56,862,870],"Platinum-Based Drug",{"nctId":872,"briefTitle":873,"status":104,"phases":874,"primaryCompletion":141,"completion":106,"start":875,"enrollment":876,"conditions":877,"interventions":879},"NCT03768570","Trimodality Therapy With\u002FOut Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer",[90],"2019-10-25",82,[878],"Bladder Cancer",[56],{"nctId":881,"briefTitle":882,"status":156,"phases":883,"primaryCompletion":141,"completion":106,"start":884,"enrollment":858,"conditions":885,"interventions":886},"NCT04918186","Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer",[90],"2022-05-03",[361],[56,887,888,889,890],"BA3011","BA3021","ENB003","Toripalimab",{"nctId":892,"briefTitle":893,"status":124,"phases":894,"primaryCompletion":895,"completion":896,"start":897,"enrollment":898,"conditions":899,"interventions":900},"NCT02788773","Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer",[90],"2021-11-22","2025-05-01","2016-12-15",52,[18],[56,862],{"nctId":902,"briefTitle":903,"status":156,"phases":904,"primaryCompletion":905,"completion":715,"start":906,"enrollment":907,"conditions":908,"interventions":910},"NCT06880523","STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma",[90],"2028-01-31","2025-10-21",140,[909],"Hepatocellular Carcinoma",[911,56,912],"STRIDE","Lenvatinib",{"nctId":914,"briefTitle":915,"status":124,"phases":916,"primaryCompletion":917,"completion":918,"start":919,"enrollment":920,"conditions":921,"interventions":923},"NCT02879318","Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma",[90],"2020-08-03","2025-03-14","2016-11-07",180,[922],"Pancreatic Adenocarcinoma",[115,924,56,862],"Nab-paclitaxel",{"nctId":926,"briefTitle":927,"status":104,"phases":928,"primaryCompletion":929,"completion":930,"start":931,"enrollment":143,"conditions":932,"interventions":934},"NCT03410615","Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC",[90],"2026-01-09","2026-07-31","2018-05-28",[933],"Oropharyngeal Squamous Cell Carcinoma",[76,56,862],{"nctId":63,"briefTitle":64,"status":104,"phases":936,"primaryCompletion":65,"completion":106,"start":937,"enrollment":836,"conditions":938,"interventions":939},[90],"2020-08-10",[15],[66,56],{"nctId":941,"briefTitle":942,"status":124,"phases":943,"primaryCompletion":944,"completion":945,"start":946,"enrollment":920,"conditions":947,"interventions":948},"NCT02870920","Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer",[90],"2018-10-18","2022-06-07","2016-10-12",[24],[862,56],{"nctId":950,"briefTitle":951,"status":124,"phases":952,"primaryCompletion":953,"completion":954,"start":955,"enrollment":907,"conditions":956,"interventions":958},"NCT02879162","Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours",[90],"2021-06-20","2025-01-29","2016-12-14",[957],"Advanced Rare Tumours",[56,862],{"trials":960,"activeCount":134},[],{"trials":962,"activeCount":134},[],{"trials":964,"activeCount":134},[],{"intervention":76,"totalTrials":966,"cells":967},10,{"EARLY_PHASE1":968,"PHASE1":974,"PHASE2":984,"PHASE3":1013,"PHASE4":1019,"NA":1021},{"trials":969,"activeCount":118,"soonestReadout":106},[970],{"nctId":102,"briefTitle":103,"status":104,"phases":971,"primaryCompletion":106,"completion":106,"start":107,"enrollment":108,"conditions":972,"interventions":973},[88],[110],[112,113,114,115,96,76,116,117],{"trials":975,"activeCount":134},[976,980],{"nctId":329,"briefTitle":330,"status":124,"phases":977,"primaryCompletion":332,"completion":333,"start":334,"enrollment":335,"conditions":978,"interventions":979},[89],[213],[338,242,339,216,76],{"nctId":122,"briefTitle":123,"status":124,"phases":981,"primaryCompletion":126,"completion":127,"start":128,"enrollment":9,"conditions":982,"interventions":983},[89],[130,131],[115,96,76,133],{"trials":985,"activeCount":25,"soonestReadout":75},[986,990,994,998,1005,1009],{"nctId":138,"briefTitle":139,"status":104,"phases":987,"primaryCompletion":141,"completion":106,"start":142,"enrollment":143,"conditions":988,"interventions":989},[90],[145],[147,113,115,96,76,148,149,150,151,152],{"nctId":154,"briefTitle":155,"status":156,"phases":991,"primaryCompletion":106,"completion":106,"start":158,"enrollment":159,"conditions":992,"interventions":993},[90],[161],[115,96,76,163,164],{"nctId":926,"briefTitle":927,"status":104,"phases":995,"primaryCompletion":929,"completion":930,"start":931,"enrollment":143,"conditions":996,"interventions":997},[90],[933],[76,56,862],{"nctId":73,"briefTitle":74,"status":104,"phases":999,"primaryCompletion":75,"completion":106,"start":1000,"enrollment":1001,"conditions":1002,"interventions":1004},[90],"2019-06-28",103,[1003],"Oropharyngeal Cancer",[76],{"nctId":351,"briefTitle":352,"status":124,"phases":1006,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":1007,"interventions":1008},[90],[359,360,361,362],[364,365,366],{"nctId":368,"briefTitle":369,"status":124,"phases":1010,"primaryCompletion":371,"completion":372,"start":373,"enrollment":374,"conditions":1011,"interventions":1012},[90],[376],[339,216,76,242],{"trials":1014,"activeCount":134},[1015],{"nctId":309,"briefTitle":310,"status":124,"phases":1016,"primaryCompletion":312,"completion":312,"start":313,"enrollment":314,"conditions":1017,"interventions":1018},[90,91],[316],[76,216,164],{"trials":1020,"activeCount":134},[],{"trials":1022,"activeCount":134},[],{"intervention":862,"totalTrials":1024,"cells":1025},8,{"EARLY_PHASE1":1026,"PHASE1":1028,"PHASE2":1034,"PHASE3":1064,"PHASE4":1066,"NA":1068},{"trials":1027,"activeCount":134},[],{"trials":1029,"activeCount":118,"soonestReadout":45},[1030],{"nctId":43,"briefTitle":44,"status":104,"phases":1031,"primaryCompletion":45,"completion":106,"start":843,"enrollment":844,"conditions":1032,"interventions":1033},[89],[846],[46,848],{"trials":1035,"activeCount":28,"soonestReadout":55},[1036,1040,1044,1048,1052,1056,1060],{"nctId":852,"briefTitle":853,"status":156,"phases":1037,"primaryCompletion":855,"completion":856,"start":857,"enrollment":858,"conditions":1038,"interventions":1039},[90],[21],[56,861,861,862],{"nctId":53,"briefTitle":54,"status":104,"phases":1041,"primaryCompletion":55,"completion":141,"start":865,"enrollment":866,"conditions":1042,"interventions":1043},[90],[868],[56,862,870],{"nctId":892,"briefTitle":893,"status":124,"phases":1045,"primaryCompletion":895,"completion":896,"start":897,"enrollment":898,"conditions":1046,"interventions":1047},[90],[18],[56,862],{"nctId":914,"briefTitle":915,"status":124,"phases":1049,"primaryCompletion":917,"completion":918,"start":919,"enrollment":920,"conditions":1050,"interventions":1051},[90],[922],[115,924,56,862],{"nctId":926,"briefTitle":927,"status":104,"phases":1053,"primaryCompletion":929,"completion":930,"start":931,"enrollment":143,"conditions":1054,"interventions":1055},[90],[933],[76,56,862],{"nctId":941,"briefTitle":942,"status":124,"phases":1057,"primaryCompletion":944,"completion":945,"start":946,"enrollment":920,"conditions":1058,"interventions":1059},[90],[24],[862,56],{"nctId":950,"briefTitle":951,"status":124,"phases":1061,"primaryCompletion":953,"completion":954,"start":955,"enrollment":907,"conditions":1062,"interventions":1063},[90],[957],[56,862],{"trials":1065,"activeCount":134},[],{"trials":1067,"activeCount":134},[],{"trials":1069,"activeCount":134},[],{"intervention":115,"totalTrials":19,"cells":1071},{"EARLY_PHASE1":1072,"PHASE1":1078,"PHASE2":1084,"PHASE3":1114,"PHASE4":1116,"NA":1118},{"trials":1073,"activeCount":118,"soonestReadout":106},[1074],{"nctId":102,"briefTitle":103,"status":104,"phases":1075,"primaryCompletion":106,"completion":106,"start":107,"enrollment":108,"conditions":1076,"interventions":1077},[88],[110],[112,113,114,115,96,76,116,117],{"trials":1079,"activeCount":134},[1080],{"nctId":122,"briefTitle":123,"status":124,"phases":1081,"primaryCompletion":126,"completion":127,"start":128,"enrollment":9,"conditions":1082,"interventions":1083},[89],[130,131],[115,96,76,133],{"trials":1085,"activeCount":28,"soonestReadout":141},[1086,1090,1094,1098,1110],{"nctId":138,"briefTitle":139,"status":104,"phases":1087,"primaryCompletion":141,"completion":106,"start":142,"enrollment":143,"conditions":1088,"interventions":1089},[90],[145],[147,113,115,96,76,148,149,150,151,152],{"nctId":154,"briefTitle":155,"status":156,"phases":1091,"primaryCompletion":106,"completion":106,"start":158,"enrollment":159,"conditions":1092,"interventions":1093},[90],[161],[115,96,76,163,164],{"nctId":914,"briefTitle":915,"status":124,"phases":1095,"primaryCompletion":917,"completion":918,"start":919,"enrollment":920,"conditions":1096,"interventions":1097},[90],[922],[115,924,56,862],{"nctId":1099,"briefTitle":1100,"status":124,"phases":1101,"primaryCompletion":1102,"completion":1103,"start":1104,"enrollment":1105,"conditions":1106,"interventions":1108},"NCT05605509","RP-6306 in Patients With Advanced Cancer",[90],"2025-11-14","2026-02-05","2023-05-24",28,[1107],"Advanced Cancer",[453,115,1109,840,455],"FOLFIRI Protocol",{"nctId":444,"briefTitle":445,"status":156,"phases":1111,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":1112,"interventions":1113},[90],[15],[453,115,454,430,455,71,66,456],{"trials":1115,"activeCount":134},[],{"trials":1117,"activeCount":134},[],{"trials":1119,"activeCount":134},[],{"intervention":66,"totalTrials":25,"cells":1121},{"EARLY_PHASE1":1122,"PHASE1":1124,"PHASE2":1126,"PHASE3":1148,"PHASE4":1150,"NA":1152},{"trials":1123,"activeCount":134},[],{"trials":1125,"activeCount":134},[],{"trials":1127,"activeCount":25,"soonestReadout":65},[1128,1136,1140,1144],{"nctId":1129,"briefTitle":1130,"status":104,"phases":1131,"primaryCompletion":141,"completion":106,"start":1132,"enrollment":1133,"conditions":1134,"interventions":1135},"NCT03624543","CFI-400945 in Patients With Advanced\u002FMetastatic Breast Cancer",[90],"2019-02-14",51,[15],[66],{"nctId":78,"briefTitle":79,"status":104,"phases":1137,"primaryCompletion":80,"completion":344,"start":345,"enrollment":224,"conditions":1138,"interventions":1139},[90],[18],[81,348,257,66,86,349,242],{"nctId":63,"briefTitle":64,"status":104,"phases":1141,"primaryCompletion":65,"completion":106,"start":937,"enrollment":836,"conditions":1142,"interventions":1143},[90],[15],[66,56],{"nctId":444,"briefTitle":445,"status":156,"phases":1145,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":1146,"interventions":1147},[90],[15],[453,115,454,430,455,71,66,456],{"trials":1149,"activeCount":134},[],{"trials":1151,"activeCount":134},[],{"trials":1153,"activeCount":134},[],{"intervention":113,"totalTrials":28,"cells":1155},{"EARLY_PHASE1":1156,"PHASE1":1162,"PHASE2":1164,"PHASE3":1181,"PHASE4":1183,"NA":1185},{"trials":1157,"activeCount":118,"soonestReadout":106},[1158],{"nctId":102,"briefTitle":103,"status":104,"phases":1159,"primaryCompletion":106,"completion":106,"start":107,"enrollment":108,"conditions":1160,"interventions":1161},[88],[110],[112,113,114,115,96,76,116,117],{"trials":1163,"activeCount":134},[],{"trials":1165,"activeCount":33,"soonestReadout":141},[1166,1170],{"nctId":138,"briefTitle":139,"status":104,"phases":1167,"primaryCompletion":141,"completion":106,"start":142,"enrollment":143,"conditions":1168,"interventions":1169},[90],[145],[147,113,115,96,76,148,149,150,151,152],{"nctId":1171,"briefTitle":1172,"status":156,"phases":1173,"primaryCompletion":1174,"completion":715,"start":1175,"enrollment":1176,"conditions":1177,"interventions":1179},"NCT05998642","Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma",[90],"2028-05-31","2024-02-13",30,[1178],"Non-hodgkin Lymphoma",[1180,113,147],"Methotrexate",{"trials":1182,"activeCount":134},[],{"trials":1184,"activeCount":134},[],{"trials":1186,"activeCount":134},[],{"intervention":338,"totalTrials":97,"cells":1188},{"EARLY_PHASE1":1189,"PHASE1":1191,"PHASE2":1197,"PHASE3":1243,"PHASE4":1245,"NA":1247},{"trials":1190,"activeCount":134},[],{"trials":1192,"activeCount":134},[1193],{"nctId":329,"briefTitle":330,"status":124,"phases":1194,"primaryCompletion":332,"completion":333,"start":334,"enrollment":335,"conditions":1195,"interventions":1196},[89],[213],[338,242,339,216,76],{"trials":1198,"activeCount":33,"soonestReadout":70},[1199,1210,1221,1227,1239],{"nctId":1200,"briefTitle":1201,"status":124,"phases":1202,"primaryCompletion":1203,"completion":1204,"start":1205,"enrollment":1206,"conditions":1207,"interventions":1208},"NCT01656538","A Study of Reolysin For Patients With Advanced\u002FMetastatic Breast Cancer",[90],"2016-11-18","2018-02-14","2013-02-20",81,[838],[338,1209],"Reolysin",{"nctId":1211,"briefTitle":1212,"status":156,"phases":1213,"primaryCompletion":141,"completion":106,"start":1214,"enrollment":1215,"conditions":1216,"interventions":1218},"NCT06043427","Paclitaxel and Ramucirumab +\u002F- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma",[90],"2024-04-16",168,[1217],"Gastroesophageal Adenocarcinoma",[338,1219,1220],"Ramucirumab","Zanidatamab",{"nctId":68,"briefTitle":69,"status":104,"phases":1222,"primaryCompletion":70,"completion":106,"start":1223,"enrollment":1224,"conditions":1225,"interventions":1226},[89,90],"2019-02-05",37,[15],[71,338],{"nctId":1228,"briefTitle":1229,"status":124,"phases":1230,"primaryCompletion":1231,"completion":1232,"start":1233,"enrollment":1234,"conditions":1235,"interventions":1237},"NCT02033993","Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.",[90],"2018-05-03","2020-10-28","2014-03-11",199,[1236],"Urothelial Cancer",[1238,338],"Nab-Paclitaxel",{"nctId":351,"briefTitle":352,"status":124,"phases":1240,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":1241,"interventions":1242},[90],[359,360,361,362],[364,365,366],{"trials":1244,"activeCount":134},[],{"trials":1246,"activeCount":134},[],{"trials":1248,"activeCount":134},[],{"intervention":149,"totalTrials":28,"cells":1250},{"EARLY_PHASE1":1251,"PHASE1":1253,"PHASE2":1270,"PHASE3":1280,"PHASE4":1282,"NA":1284},{"trials":1252,"activeCount":134},[],{"trials":1254,"activeCount":118,"soonestReadout":1260},[1255],{"nctId":1256,"briefTitle":1257,"status":1258,"phases":1259,"primaryCompletion":1260,"completion":1261,"start":1262,"enrollment":1176,"conditions":1263,"interventions":1267},"NCT07297667","GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed\u002FRefractory GPNMB-Expressing Solid Tumours","NOT_YET_RECRUITING",[89],"2028-12-01","2033-09-01","2026-05-01",[1264,1265,1266],"Alveolar Soft Part Sarcoma","Renal Cell Carcinoma","Triple Negative Breast Cancer",[1268,149,1269],"Fludarabine","GCAR1",{"trials":1271,"activeCount":118,"soonestReadout":141},[1272,1276],{"nctId":138,"briefTitle":139,"status":104,"phases":1273,"primaryCompletion":141,"completion":106,"start":142,"enrollment":143,"conditions":1274,"interventions":1275},[90],[145],[147,113,115,96,76,148,149,150,151,152],{"nctId":166,"briefTitle":167,"status":124,"phases":1277,"primaryCompletion":169,"completion":170,"start":171,"enrollment":172,"conditions":1278,"interventions":1279},[90],[30],[175,149,96],{"trials":1281,"activeCount":134},[],{"trials":1283,"activeCount":134},[],{"trials":1285,"activeCount":134},[],{"intervention":1287,"totalTrials":28,"cells":1288},"Temsirolimus",{"EARLY_PHASE1":1289,"PHASE1":1291,"PHASE2":1307,"PHASE3":1337,"PHASE4":1339,"NA":1341},{"trials":1290,"activeCount":134},[],{"trials":1292,"activeCount":134},[1293],{"nctId":1294,"briefTitle":1295,"status":124,"phases":1296,"primaryCompletion":1297,"completion":1298,"start":1299,"enrollment":19,"conditions":1300,"interventions":1305},"NCT02343718","Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours",[89],"2017-09-28","2019-01-16","2015-06-24",[1301,1302,1303,1304],"Recurrent Lymphoma","Refractory Lymphoma","Solid Tumours","Central Nervous System",[1306,1287],"Vinblastine",{"trials":1308,"activeCount":33,"soonestReadout":40},[1309,1315],{"nctId":38,"briefTitle":39,"status":104,"phases":1310,"primaryCompletion":40,"completion":141,"start":1311,"enrollment":1312,"conditions":1313,"interventions":1314},[90],"2012-02-09",137,[957],[41,1287],{"nctId":1316,"briefTitle":1317,"status":156,"phases":1318,"primaryCompletion":106,"completion":1319,"start":1320,"enrollment":1321,"conditions":1322,"interventions":1325},"NCT03297606","Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)",[90],"2027-01-31","2018-03-23",720,[1323,30,1324],"Lymphoma, Non-Hodgkin","Advanced Solid Tumors",[1326,1327,1328,1329,1330,1331,61,41,1287,1332,1333,1334,1335,1336],"Olaparib","Dasatinib","Nivolumab plus Ipilimumab","Axitinib","Bosutinib","Crizotinib","Erlotinib","Trastuzumab plus Pertuzumab","Vemurafenib plus Cobimetinib","Vismodegib","Tucatinib",{"trials":1338,"activeCount":134},[],{"trials":1340,"activeCount":134},[],{"trials":1342,"activeCount":134},[],{"intervention":147,"totalTrials":33,"cells":1344},{"EARLY_PHASE1":1345,"PHASE1":1347,"PHASE2":1349,"PHASE3":1359,"PHASE4":1361,"NA":1363},{"trials":1346,"activeCount":134},[],{"trials":1348,"activeCount":134},[],{"trials":1350,"activeCount":33,"soonestReadout":141},[1351,1355],{"nctId":138,"briefTitle":139,"status":104,"phases":1352,"primaryCompletion":141,"completion":106,"start":142,"enrollment":143,"conditions":1353,"interventions":1354},[90],[145],[147,113,115,96,76,148,149,150,151,152],{"nctId":1171,"briefTitle":1172,"status":156,"phases":1356,"primaryCompletion":1174,"completion":715,"start":1175,"enrollment":1176,"conditions":1357,"interventions":1358},[90],[1178],[1180,113,147],{"trials":1360,"activeCount":134},[],{"trials":1362,"activeCount":134},[],{"trials":1364,"activeCount":134},[],{"intervention":41,"totalTrials":33,"cells":1366},{"EARLY_PHASE1":1367,"PHASE1":1369,"PHASE2":1371,"PHASE3":1381,"PHASE4":1383,"NA":1385},{"trials":1368,"activeCount":134},[],{"trials":1370,"activeCount":134},[],{"trials":1372,"activeCount":33,"soonestReadout":40},[1373,1377],{"nctId":38,"briefTitle":39,"status":104,"phases":1374,"primaryCompletion":40,"completion":141,"start":1311,"enrollment":1312,"conditions":1375,"interventions":1376},[90],[957],[41,1287],{"nctId":1316,"briefTitle":1317,"status":156,"phases":1378,"primaryCompletion":106,"completion":1319,"start":1320,"enrollment":1321,"conditions":1379,"interventions":1380},[90],[1323,30,1324],[1326,1327,1328,1329,1330,1331,61,41,1287,1332,1333,1334,1335,1336],{"trials":1382,"activeCount":134},[],{"trials":1384,"activeCount":134},[],{"trials":1386,"activeCount":134},[],{"intervention":61,"totalTrials":33,"cells":1388},{"EARLY_PHASE1":1389,"PHASE1":1391,"PHASE2":1393,"PHASE3":1406,"PHASE4":1408,"NA":1410},{"trials":1390,"activeCount":134},[],{"trials":1392,"activeCount":134},[],{"trials":1394,"activeCount":33,"soonestReadout":60},[1395,1399],{"nctId":1316,"briefTitle":1317,"status":156,"phases":1396,"primaryCompletion":106,"completion":1319,"start":1320,"enrollment":1321,"conditions":1397,"interventions":1398},[90],[1323,30,1324],[1326,1327,1328,1329,1330,1331,61,41,1287,1332,1333,1334,1335,1336],{"nctId":58,"briefTitle":59,"status":104,"phases":1400,"primaryCompletion":60,"completion":1401,"start":1402,"enrollment":1403,"conditions":1404,"interventions":1405},[90],"2026-12-30","2017-07-04",19,[18],[61],{"trials":1407,"activeCount":134},[],{"trials":1409,"activeCount":134},[],{"trials":1411,"activeCount":134},[],{"intervention":71,"totalTrials":33,"cells":1413},{"EARLY_PHASE1":1414,"PHASE1":1416,"PHASE2":1418,"PHASE3":1428,"PHASE4":1430,"NA":1432},{"trials":1415,"activeCount":134},[],{"trials":1417,"activeCount":134},[],{"trials":1419,"activeCount":33,"soonestReadout":70},[1420,1424],{"nctId":68,"briefTitle":69,"status":104,"phases":1421,"primaryCompletion":70,"completion":106,"start":1223,"enrollment":1224,"conditions":1422,"interventions":1423},[89,90],[15],[71,338],{"nctId":444,"briefTitle":445,"status":156,"phases":1425,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":1426,"interventions":1427},[90],[15],[453,115,454,430,455,71,66,456],{"trials":1429,"activeCount":134},[],{"trials":1431,"activeCount":134},[],{"trials":1433,"activeCount":134},[],{"intervention":453,"totalTrials":33,"cells":1435},{"EARLY_PHASE1":1436,"PHASE1":1438,"PHASE2":1440,"PHASE3":1450,"PHASE4":1452,"NA":1454},{"trials":1437,"activeCount":134},[],{"trials":1439,"activeCount":134},[],{"trials":1441,"activeCount":118,"soonestReadout":447},[1442,1446],{"nctId":1099,"briefTitle":1100,"status":124,"phases":1443,"primaryCompletion":1102,"completion":1103,"start":1104,"enrollment":1105,"conditions":1444,"interventions":1445},[90],[1107],[453,115,1109,840,455],{"nctId":444,"briefTitle":445,"status":156,"phases":1447,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":1448,"interventions":1449},[90],[15],[453,115,454,430,455,71,66,456],{"trials":1451,"activeCount":134},[],{"trials":1453,"activeCount":134},[],{"trials":1455,"activeCount":134},[],{"intervention":455,"totalTrials":33,"cells":1457},{"EARLY_PHASE1":1458,"PHASE1":1460,"PHASE2":1462,"PHASE3":1472,"PHASE4":1474,"NA":1476},{"trials":1459,"activeCount":134},[],{"trials":1461,"activeCount":134},[],{"trials":1463,"activeCount":118,"soonestReadout":447},[1464,1468],{"nctId":1099,"briefTitle":1100,"status":124,"phases":1465,"primaryCompletion":1102,"completion":1103,"start":1104,"enrollment":1105,"conditions":1466,"interventions":1467},[90],[1107],[453,115,1109,840,455],{"nctId":444,"briefTitle":445,"status":156,"phases":1469,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":1470,"interventions":1471},[90],[15],[453,115,454,430,455,71,66,456],{"trials":1473,"activeCount":134},[],{"trials":1475,"activeCount":134},[],{"trials":1477,"activeCount":134},[],{"intervention":148,"totalTrials":118,"cells":1479},{"EARLY_PHASE1":1480,"PHASE1":1482,"PHASE2":1484,"PHASE3":1490,"PHASE4":1492,"NA":1494},{"trials":1481,"activeCount":134},[],{"trials":1483,"activeCount":134},[],{"trials":1485,"activeCount":118,"soonestReadout":141},[1486],{"nctId":138,"briefTitle":139,"status":104,"phases":1487,"primaryCompletion":141,"completion":106,"start":142,"enrollment":143,"conditions":1488,"interventions":1489},[90],[145],[147,113,115,96,76,148,149,150,151,152],{"trials":1491,"activeCount":134},[],{"trials":1493,"activeCount":134},[],{"trials":1495,"activeCount":134},[],{"intervention":150,"totalTrials":118,"cells":1497},{"EARLY_PHASE1":1498,"PHASE1":1500,"PHASE2":1502,"PHASE3":1508,"PHASE4":1510,"NA":1512},{"trials":1499,"activeCount":134},[],{"trials":1501,"activeCount":134},[],{"trials":1503,"activeCount":118,"soonestReadout":141},[1504],{"nctId":138,"briefTitle":139,"status":104,"phases":1505,"primaryCompletion":141,"completion":106,"start":142,"enrollment":143,"conditions":1506,"interventions":1507},[90],[145],[147,113,115,96,76,148,149,150,151,152],{"trials":1509,"activeCount":134},[],{"trials":1511,"activeCount":134},[],{"trials":1513,"activeCount":134},[],{"intervention":151,"totalTrials":118,"cells":1515},{"EARLY_PHASE1":1516,"PHASE1":1518,"PHASE2":1520,"PHASE3":1526,"PHASE4":1528,"NA":1530},{"trials":1517,"activeCount":134},[],{"trials":1519,"activeCount":134},[],{"trials":1521,"activeCount":118,"soonestReadout":141},[1522],{"nctId":138,"briefTitle":139,"status":104,"phases":1523,"primaryCompletion":141,"completion":106,"start":142,"enrollment":143,"conditions":1524,"interventions":1525},[90],[145],[147,113,115,96,76,148,149,150,151,152],{"trials":1527,"activeCount":134},[],{"trials":1529,"activeCount":134},[],{"trials":1531,"activeCount":134},[],{"intervention":152,"totalTrials":118,"cells":1533},{"EARLY_PHASE1":1534,"PHASE1":1536,"PHASE2":1538,"PHASE3":1544,"PHASE4":1546,"NA":1548},{"trials":1535,"activeCount":134},[],{"trials":1537,"activeCount":134},[],{"trials":1539,"activeCount":118,"soonestReadout":141},[1540],{"nctId":138,"briefTitle":139,"status":104,"phases":1541,"primaryCompletion":141,"completion":106,"start":142,"enrollment":143,"conditions":1542,"interventions":1543},[90],[145],[147,113,115,96,76,148,149,150,151,152],{"trials":1545,"activeCount":134},[],{"trials":1547,"activeCount":134},[],{"trials":1549,"activeCount":134},[],{"intervention":861,"totalTrials":118,"cells":1551},{"EARLY_PHASE1":1552,"PHASE1":1554,"PHASE2":1556,"PHASE3":1562,"PHASE4":1564,"NA":1566},{"trials":1553,"activeCount":134},[],{"trials":1555,"activeCount":134},[],{"trials":1557,"activeCount":118,"soonestReadout":855},[1558],{"nctId":852,"briefTitle":853,"status":156,"phases":1559,"primaryCompletion":855,"completion":856,"start":857,"enrollment":858,"conditions":1560,"interventions":1561},[90],[21],[56,861,861,862],{"trials":1563,"activeCount":134},[],{"trials":1565,"activeCount":134},[],{"trials":1567,"activeCount":134},[],{"intervention":51,"totalTrials":118,"cells":1569},{"EARLY_PHASE1":1570,"PHASE1":1572,"PHASE2":1574,"PHASE3":1584,"PHASE4":1586,"NA":1588},{"trials":1571,"activeCount":134},[],{"trials":1573,"activeCount":134},[],{"trials":1575,"activeCount":118,"soonestReadout":50},[1576],{"nctId":48,"briefTitle":49,"status":104,"phases":1577,"primaryCompletion":50,"completion":106,"start":1578,"enrollment":1579,"conditions":1580,"interventions":1582},[89,90],"2015-01-22",56,[1581],"Advanced\u002FMetastatic Solid Tumours",[51,1583],"AdMA3",{"trials":1585,"activeCount":134},[],{"trials":1587,"activeCount":134},[],{"trials":1589,"activeCount":134},[],{"intervention":1583,"totalTrials":118,"cells":1591},{"EARLY_PHASE1":1592,"PHASE1":1594,"PHASE2":1596,"PHASE3":1602,"PHASE4":1604,"NA":1606},{"trials":1593,"activeCount":134},[],{"trials":1595,"activeCount":134},[],{"trials":1597,"activeCount":118,"soonestReadout":50},[1598],{"nctId":48,"briefTitle":49,"status":104,"phases":1599,"primaryCompletion":50,"completion":106,"start":1578,"enrollment":1579,"conditions":1600,"interventions":1601},[89,90],[1581],[51,1583],{"trials":1603,"activeCount":134},[],{"trials":1605,"activeCount":134},[],{"trials":1607,"activeCount":134},[],{"intervention":870,"totalTrials":118,"cells":1609},{"EARLY_PHASE1":1610,"PHASE1":1612,"PHASE2":1614,"PHASE3":1620,"PHASE4":1622,"NA":1624},{"trials":1611,"activeCount":134},[],{"trials":1613,"activeCount":134},[],{"trials":1615,"activeCount":118,"soonestReadout":55},[1616],{"nctId":53,"briefTitle":54,"status":104,"phases":1617,"primaryCompletion":55,"completion":141,"start":865,"enrollment":866,"conditions":1618,"interventions":1619},[90],[868],[56,862,870],{"trials":1621,"activeCount":134},[],{"trials":1623,"activeCount":134},[],{"trials":1625,"activeCount":134},[],{"intervention":163,"totalTrials":118,"cells":1627},{"EARLY_PHASE1":1628,"PHASE1":1630,"PHASE2":1632,"PHASE3":1638,"PHASE4":1640,"NA":1642},{"trials":1629,"activeCount":134},[],{"trials":1631,"activeCount":134},[],{"trials":1633,"activeCount":118,"soonestReadout":106},[1634],{"nctId":154,"briefTitle":155,"status":156,"phases":1635,"primaryCompletion":106,"completion":106,"start":158,"enrollment":159,"conditions":1636,"interventions":1637},[90],[161],[115,96,76,163,164],{"trials":1639,"activeCount":134},[],{"trials":1641,"activeCount":134},[],{"trials":1643,"activeCount":134},[],{"intervention":1645,"totalTrials":118,"cells":1646},"Standard of Care Immune Checkpoint Blockade",{"EARLY_PHASE1":1647,"PHASE1":1649,"PHASE2":1651,"PHASE3":1662,"PHASE4":1664,"NA":1666},{"trials":1648,"activeCount":134},[],{"trials":1650,"activeCount":134},[],{"trials":1652,"activeCount":118,"soonestReadout":715},[1653],{"nctId":1654,"briefTitle":1655,"status":156,"phases":1656,"primaryCompletion":715,"completion":510,"start":1657,"enrollment":1658,"conditions":1659,"interventions":1660},"NCT06623461","LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma",[90],"2025-04-07",128,[32],[1645,1661],"LND101",{"trials":1663,"activeCount":134},[],{"trials":1665,"activeCount":134},[],{"trials":1667,"activeCount":134},[],{"intervention":1661,"totalTrials":118,"cells":1669},{"EARLY_PHASE1":1670,"PHASE1":1672,"PHASE2":1674,"PHASE3":1680,"PHASE4":1682,"NA":1684},{"trials":1671,"activeCount":134},[],{"trials":1673,"activeCount":134},[],{"trials":1675,"activeCount":118,"soonestReadout":715},[1676],{"nctId":1654,"briefTitle":1655,"status":156,"phases":1677,"primaryCompletion":715,"completion":510,"start":1657,"enrollment":1658,"conditions":1678,"interventions":1679},[90],[32],[1645,1661],{"trials":1681,"activeCount":134},[],{"trials":1683,"activeCount":134},[],{"trials":1685,"activeCount":134},[],{"intervention":1687,"totalTrials":118,"cells":1688},"JDQ443",{"EARLY_PHASE1":1689,"PHASE1":1691,"PHASE2":1693,"PHASE3":1705,"PHASE4":1707,"NA":1709},{"trials":1690,"activeCount":134},[],{"trials":1692,"activeCount":134},[],{"trials":1694,"activeCount":118,"soonestReadout":1699},[1695],{"nctId":1696,"briefTitle":1697,"status":104,"phases":1698,"primaryCompletion":1699,"completion":1700,"start":1701,"enrollment":25,"conditions":1702,"interventions":1704},"NCT05714891","Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer",[90],"2026-08-31","2028-03-31","2023-09-15",[1703],"NSCLC",[1687],{"trials":1706,"activeCount":134},[],{"trials":1708,"activeCount":134},[],{"trials":1710,"activeCount":134},[],{"intervention":81,"totalTrials":118,"cells":1712},{"EARLY_PHASE1":1713,"PHASE1":1715,"PHASE2":1717,"PHASE3":1723,"PHASE4":1725,"NA":1727},{"trials":1714,"activeCount":134},[],{"trials":1716,"activeCount":134},[],{"trials":1718,"activeCount":118,"soonestReadout":80},[1719],{"nctId":78,"briefTitle":79,"status":104,"phases":1720,"primaryCompletion":80,"completion":344,"start":345,"enrollment":224,"conditions":1721,"interventions":1722},[90],[18],[81,348,257,66,86,349,242],{"trials":1724,"activeCount":134},[],{"trials":1726,"activeCount":134},[],{"trials":1728,"activeCount":134},[],{"intervention":348,"totalTrials":118,"cells":1730},{"EARLY_PHASE1":1731,"PHASE1":1733,"PHASE2":1735,"PHASE3":1741,"PHASE4":1743,"NA":1745},{"trials":1732,"activeCount":134},[],{"trials":1734,"activeCount":134},[],{"trials":1736,"activeCount":118,"soonestReadout":80},[1737],{"nctId":78,"briefTitle":79,"status":104,"phases":1738,"primaryCompletion":80,"completion":344,"start":345,"enrollment":224,"conditions":1739,"interventions":1740},[90],[18],[81,348,257,66,86,349,242],{"trials":1742,"activeCount":134},[],{"trials":1744,"activeCount":134},[],{"trials":1746,"activeCount":134},[],{"intervention":349,"totalTrials":118,"cells":1748},{"EARLY_PHASE1":1749,"PHASE1":1751,"PHASE2":1753,"PHASE3":1759,"PHASE4":1761,"NA":1763},{"trials":1750,"activeCount":134},[],{"trials":1752,"activeCount":134},[],{"trials":1754,"activeCount":118,"soonestReadout":80},[1755],{"nctId":78,"briefTitle":79,"status":104,"phases":1756,"primaryCompletion":80,"completion":344,"start":345,"enrollment":224,"conditions":1757,"interventions":1758},[90],[18],[81,348,257,66,86,349,242],{"trials":1760,"activeCount":134},[],{"trials":1762,"activeCount":134},[],{"trials":1764,"activeCount":134},[],{"intervention":887,"totalTrials":118,"cells":1766},{"EARLY_PHASE1":1767,"PHASE1":1769,"PHASE2":1771,"PHASE3":1777,"PHASE4":1779,"NA":1781},{"trials":1768,"activeCount":134},[],{"trials":1770,"activeCount":134},[],{"trials":1772,"activeCount":118,"soonestReadout":141},[1773],{"nctId":881,"briefTitle":882,"status":156,"phases":1774,"primaryCompletion":141,"completion":106,"start":884,"enrollment":858,"conditions":1775,"interventions":1776},[90],[361],[56,887,888,889,890],{"trials":1778,"activeCount":134},[],{"trials":1780,"activeCount":134},[],{"trials":1782,"activeCount":134},[],{"intervention":888,"totalTrials":118,"cells":1784},{"EARLY_PHASE1":1785,"PHASE1":1787,"PHASE2":1789,"PHASE3":1795,"PHASE4":1797,"NA":1799},{"trials":1786,"activeCount":134},[],{"trials":1788,"activeCount":134},[],{"trials":1790,"activeCount":118,"soonestReadout":141},[1791],{"nctId":881,"briefTitle":882,"status":156,"phases":1792,"primaryCompletion":141,"completion":106,"start":884,"enrollment":858,"conditions":1793,"interventions":1794},[90],[361],[56,887,888,889,890],{"trials":1796,"activeCount":134},[],{"trials":1798,"activeCount":134},[],{"trials":1800,"activeCount":134},[],{"intervention":889,"totalTrials":118,"cells":1802},{"EARLY_PHASE1":1803,"PHASE1":1805,"PHASE2":1807,"PHASE3":1813,"PHASE4":1815,"NA":1817},{"trials":1804,"activeCount":134},[],{"trials":1806,"activeCount":134},[],{"trials":1808,"activeCount":118,"soonestReadout":141},[1809],{"nctId":881,"briefTitle":882,"status":156,"phases":1810,"primaryCompletion":141,"completion":106,"start":884,"enrollment":858,"conditions":1811,"interventions":1812},[90],[361],[56,887,888,889,890],{"trials":1814,"activeCount":134},[],{"trials":1816,"activeCount":134},[],{"trials":1818,"activeCount":134},[],{"intervention":890,"totalTrials":118,"cells":1820},{"EARLY_PHASE1":1821,"PHASE1":1823,"PHASE2":1825,"PHASE3":1831,"PHASE4":1833,"NA":1835},{"trials":1822,"activeCount":134},[],{"trials":1824,"activeCount":134},[],{"trials":1826,"activeCount":118,"soonestReadout":141},[1827],{"nctId":881,"briefTitle":882,"status":156,"phases":1828,"primaryCompletion":141,"completion":106,"start":884,"enrollment":858,"conditions":1829,"interventions":1830},[90],[361],[56,887,888,889,890],{"trials":1832,"activeCount":134},[],{"trials":1834,"activeCount":134},[],{"trials":1836,"activeCount":134},[],{"intervention":1219,"totalTrials":118,"cells":1838},{"EARLY_PHASE1":1839,"PHASE1":1841,"PHASE2":1843,"PHASE3":1849,"PHASE4":1851,"NA":1853},{"trials":1840,"activeCount":134},[],{"trials":1842,"activeCount":134},[],{"trials":1844,"activeCount":118,"soonestReadout":141},[1845],{"nctId":1211,"briefTitle":1212,"status":156,"phases":1846,"primaryCompletion":141,"completion":106,"start":1214,"enrollment":1215,"conditions":1847,"interventions":1848},[90],[1217],[338,1219,1220],{"trials":1850,"activeCount":134},[],{"trials":1852,"activeCount":134},[],{"trials":1854,"activeCount":134},[],{"intervention":1220,"totalTrials":118,"cells":1856},{"EARLY_PHASE1":1857,"PHASE1":1859,"PHASE2":1861,"PHASE3":1867,"PHASE4":1869,"NA":1871},{"trials":1858,"activeCount":134},[],{"trials":1860,"activeCount":134},[],{"trials":1862,"activeCount":118,"soonestReadout":141},[1863],{"nctId":1211,"briefTitle":1212,"status":156,"phases":1864,"primaryCompletion":141,"completion":106,"start":1214,"enrollment":1215,"conditions":1865,"interventions":1866},[90],[1217],[338,1219,1220],{"trials":1868,"activeCount":134},[],{"trials":1870,"activeCount":134},[],{"trials":1872,"activeCount":134},[],{"intervention":911,"totalTrials":118,"cells":1874},{"EARLY_PHASE1":1875,"PHASE1":1877,"PHASE2":1879,"PHASE3":1885,"PHASE4":1887,"NA":1889},{"trials":1876,"activeCount":134},[],{"trials":1878,"activeCount":134},[],{"trials":1880,"activeCount":118,"soonestReadout":905},[1881],{"nctId":902,"briefTitle":903,"status":156,"phases":1882,"primaryCompletion":905,"completion":715,"start":906,"enrollment":907,"conditions":1883,"interventions":1884},[90],[909],[911,56,912],{"trials":1886,"activeCount":134},[],{"trials":1888,"activeCount":134},[],{"trials":1890,"activeCount":134},[],{"intervention":912,"totalTrials":118,"cells":1892},{"EARLY_PHASE1":1893,"PHASE1":1895,"PHASE2":1897,"PHASE3":1903,"PHASE4":1905,"NA":1907},{"trials":1894,"activeCount":134},[],{"trials":1896,"activeCount":134},[],{"trials":1898,"activeCount":118,"soonestReadout":905},[1899],{"nctId":902,"briefTitle":903,"status":156,"phases":1900,"primaryCompletion":905,"completion":715,"start":906,"enrollment":907,"conditions":1901,"interventions":1902},[90],[909],[911,56,912],{"trials":1904,"activeCount":134},[],{"trials":1906,"activeCount":134},[],{"trials":1908,"activeCount":134},[],{"intervention":1180,"totalTrials":118,"cells":1910},{"EARLY_PHASE1":1911,"PHASE1":1913,"PHASE2":1915,"PHASE3":1921,"PHASE4":1923,"NA":1925},{"trials":1912,"activeCount":134},[],{"trials":1914,"activeCount":134},[],{"trials":1916,"activeCount":118,"soonestReadout":1174},[1917],{"nctId":1171,"briefTitle":1172,"status":156,"phases":1918,"primaryCompletion":1174,"completion":715,"start":1175,"enrollment":1176,"conditions":1919,"interventions":1920},[90],[1178],[1180,113,147],{"trials":1922,"activeCount":134},[],{"trials":1924,"activeCount":134},[],{"trials":1926,"activeCount":134},[],{"intervention":1326,"totalTrials":118,"cells":1928},{"EARLY_PHASE1":1929,"PHASE1":1931,"PHASE2":1933,"PHASE3":1939,"PHASE4":1941,"NA":1943},{"trials":1930,"activeCount":134},[],{"trials":1932,"activeCount":134},[],{"trials":1934,"activeCount":118,"soonestReadout":106},[1935],{"nctId":1316,"briefTitle":1317,"status":156,"phases":1936,"primaryCompletion":106,"completion":1319,"start":1320,"enrollment":1321,"conditions":1937,"interventions":1938},[90],[1323,30,1324],[1326,1327,1328,1329,1330,1331,61,41,1287,1332,1333,1334,1335,1336],{"trials":1940,"activeCount":134},[],{"trials":1942,"activeCount":134},[],{"trials":1944,"activeCount":134},[],{"intervention":1327,"totalTrials":118,"cells":1946},{"EARLY_PHASE1":1947,"PHASE1":1949,"PHASE2":1951,"PHASE3":1957,"PHASE4":1959,"NA":1961},{"trials":1948,"activeCount":134},[],{"trials":1950,"activeCount":134},[],{"trials":1952,"activeCount":118,"soonestReadout":106},[1953],{"nctId":1316,"briefTitle":1317,"status":156,"phases":1954,"primaryCompletion":106,"completion":1319,"start":1320,"enrollment":1321,"conditions":1955,"interventions":1956},[90],[1323,30,1324],[1326,1327,1328,1329,1330,1331,61,41,1287,1332,1333,1334,1335,1336],{"trials":1958,"activeCount":134},[],{"trials":1960,"activeCount":134},[],{"trials":1962,"activeCount":134},[],{"intervention":1328,"totalTrials":118,"cells":1964},{"EARLY_PHASE1":1965,"PHASE1":1967,"PHASE2":1969,"PHASE3":1975,"PHASE4":1977,"NA":1979},{"trials":1966,"activeCount":134},[],{"trials":1968,"activeCount":134},[],{"trials":1970,"activeCount":118,"soonestReadout":106},[1971],{"nctId":1316,"briefTitle":1317,"status":156,"phases":1972,"primaryCompletion":106,"completion":1319,"start":1320,"enrollment":1321,"conditions":1973,"interventions":1974},[90],[1323,30,1324],[1326,1327,1328,1329,1330,1331,61,41,1287,1332,1333,1334,1335,1336],{"trials":1976,"activeCount":134},[],{"trials":1978,"activeCount":134},[],{"trials":1980,"activeCount":134},[],{"intervention":1329,"totalTrials":118,"cells":1982},{"EARLY_PHASE1":1983,"PHASE1":1985,"PHASE2":1987,"PHASE3":1993,"PHASE4":1995,"NA":1997},{"trials":1984,"activeCount":134},[],{"trials":1986,"activeCount":134},[],{"trials":1988,"activeCount":118,"soonestReadout":106},[1989],{"nctId":1316,"briefTitle":1317,"status":156,"phases":1990,"primaryCompletion":106,"completion":1319,"start":1320,"enrollment":1321,"conditions":1991,"interventions":1992},[90],[1323,30,1324],[1326,1327,1328,1329,1330,1331,61,41,1287,1332,1333,1334,1335,1336],{"trials":1994,"activeCount":134},[],{"trials":1996,"activeCount":134},[],{"trials":1998,"activeCount":134},[],{"intervention":1330,"totalTrials":118,"cells":2000},{"EARLY_PHASE1":2001,"PHASE1":2003,"PHASE2":2005,"PHASE3":2011,"PHASE4":2013,"NA":2015},{"trials":2002,"activeCount":134},[],{"trials":2004,"activeCount":134},[],{"trials":2006,"activeCount":118,"soonestReadout":106},[2007],{"nctId":1316,"briefTitle":1317,"status":156,"phases":2008,"primaryCompletion":106,"completion":1319,"start":1320,"enrollment":1321,"conditions":2009,"interventions":2010},[90],[1323,30,1324],[1326,1327,1328,1329,1330,1331,61,41,1287,1332,1333,1334,1335,1336],{"trials":2012,"activeCount":134},[],{"trials":2014,"activeCount":134},[],{"trials":2016,"activeCount":134},[],{"intervention":1331,"totalTrials":118,"cells":2018},{"EARLY_PHASE1":2019,"PHASE1":2021,"PHASE2":2023,"PHASE3":2029,"PHASE4":2031,"NA":2033},{"trials":2020,"activeCount":134},[],{"trials":2022,"activeCount":134},[],{"trials":2024,"activeCount":118,"soonestReadout":106},[2025],{"nctId":1316,"briefTitle":1317,"status":156,"phases":2026,"primaryCompletion":106,"completion":1319,"start":1320,"enrollment":1321,"conditions":2027,"interventions":2028},[90],[1323,30,1324],[1326,1327,1328,1329,1330,1331,61,41,1287,1332,1333,1334,1335,1336],{"trials":2030,"activeCount":134},[],{"trials":2032,"activeCount":134},[],{"trials":2034,"activeCount":134},[],{"intervention":1332,"totalTrials":118,"cells":2036},{"EARLY_PHASE1":2037,"PHASE1":2039,"PHASE2":2041,"PHASE3":2047,"PHASE4":2049,"NA":2051},{"trials":2038,"activeCount":134},[],{"trials":2040,"activeCount":134},[],{"trials":2042,"activeCount":118,"soonestReadout":106},[2043],{"nctId":1316,"briefTitle":1317,"status":156,"phases":2044,"primaryCompletion":106,"completion":1319,"start":1320,"enrollment":1321,"conditions":2045,"interventions":2046},[90],[1323,30,1324],[1326,1327,1328,1329,1330,1331,61,41,1287,1332,1333,1334,1335,1336],{"trials":2048,"activeCount":134},[],{"trials":2050,"activeCount":134},[],{"trials":2052,"activeCount":134},[],{"intervention":1333,"totalTrials":118,"cells":2054},{"EARLY_PHASE1":2055,"PHASE1":2057,"PHASE2":2059,"PHASE3":2065,"PHASE4":2067,"NA":2069},{"trials":2056,"activeCount":134},[],{"trials":2058,"activeCount":134},[],{"trials":2060,"activeCount":118,"soonestReadout":106},[2061],{"nctId":1316,"briefTitle":1317,"status":156,"phases":2062,"primaryCompletion":106,"completion":1319,"start":1320,"enrollment":1321,"conditions":2063,"interventions":2064},[90],[1323,30,1324],[1326,1327,1328,1329,1330,1331,61,41,1287,1332,1333,1334,1335,1336],{"trials":2066,"activeCount":134},[],{"trials":2068,"activeCount":134},[],{"trials":2070,"activeCount":134},[],{"intervention":1334,"totalTrials":118,"cells":2072},{"EARLY_PHASE1":2073,"PHASE1":2075,"PHASE2":2077,"PHASE3":2083,"PHASE4":2085,"NA":2087},{"trials":2074,"activeCount":134},[],{"trials":2076,"activeCount":134},[],{"trials":2078,"activeCount":118,"soonestReadout":106},[2079],{"nctId":1316,"briefTitle":1317,"status":156,"phases":2080,"primaryCompletion":106,"completion":1319,"start":1320,"enrollment":1321,"conditions":2081,"interventions":2082},[90],[1323,30,1324],[1326,1327,1328,1329,1330,1331,61,41,1287,1332,1333,1334,1335,1336],{"trials":2084,"activeCount":134},[],{"trials":2086,"activeCount":134},[],{"trials":2088,"activeCount":134},[],{"intervention":1335,"totalTrials":118,"cells":2090},{"EARLY_PHASE1":2091,"PHASE1":2093,"PHASE2":2095,"PHASE3":2101,"PHASE4":2103,"NA":2105},{"trials":2092,"activeCount":134},[],{"trials":2094,"activeCount":134},[],{"trials":2096,"activeCount":118,"soonestReadout":106},[2097],{"nctId":1316,"briefTitle":1317,"status":156,"phases":2098,"primaryCompletion":106,"completion":1319,"start":1320,"enrollment":1321,"conditions":2099,"interventions":2100},[90],[1323,30,1324],[1326,1327,1328,1329,1330,1331,61,41,1287,1332,1333,1334,1335,1336],{"trials":2102,"activeCount":134},[],{"trials":2104,"activeCount":134},[],{"trials":2106,"activeCount":134},[],{"intervention":1336,"totalTrials":118,"cells":2108},{"EARLY_PHASE1":2109,"PHASE1":2111,"PHASE2":2113,"PHASE3":2119,"PHASE4":2121,"NA":2123},{"trials":2110,"activeCount":134},[],{"trials":2112,"activeCount":134},[],{"trials":2114,"activeCount":118,"soonestReadout":106},[2115],{"nctId":1316,"briefTitle":1317,"status":156,"phases":2116,"primaryCompletion":106,"completion":1319,"start":1320,"enrollment":1321,"conditions":2117,"interventions":2118},[90],[1323,30,1324],[1326,1327,1328,1329,1330,1331,61,41,1287,1332,1333,1334,1335,1336],{"trials":2120,"activeCount":134},[],{"trials":2122,"activeCount":134},[],{"trials":2124,"activeCount":134},[],{"intervention":227,"totalTrials":118,"cells":2126},{"EARLY_PHASE1":2127,"PHASE1":2129,"PHASE2":2131,"PHASE3":2137,"PHASE4":2139,"NA":2141},{"trials":2128,"activeCount":134},[],{"trials":2130,"activeCount":134},[],{"trials":2132,"activeCount":118,"soonestReadout":222},[2133],{"nctId":219,"briefTitle":220,"status":104,"phases":2134,"primaryCompletion":222,"completion":106,"start":223,"enrollment":224,"conditions":2135,"interventions":2136},[90],[18],[227,196],{"trials":2138,"activeCount":134},[],{"trials":2140,"activeCount":134},[],{"trials":2142,"activeCount":134},[],{"intervention":2144,"totalTrials":118,"cells":2145},"Zanubrutinib",{"EARLY_PHASE1":2146,"PHASE1":2148,"PHASE2":2150,"PHASE3":2162,"PHASE4":2164,"NA":2166},{"trials":2147,"activeCount":134},[],{"trials":2149,"activeCount":134},[],{"trials":2151,"activeCount":118,"soonestReadout":510},[2152],{"nctId":2153,"briefTitle":2154,"status":156,"phases":2155,"primaryCompletion":510,"completion":2156,"start":141,"enrollment":108,"conditions":2157,"interventions":2159},"NCT07341191","Sonrotoclax Plus Zanubrutinib in Patients With Relapsed\u002FRefractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy",[90],"2030-12-31",[2158],"Mantle Cell Lymphoma",[2144,2160,2161],"Sonrotoclax","CAR-T Cell Therapy",{"trials":2163,"activeCount":134},[],{"trials":2165,"activeCount":134},[],{"trials":2167,"activeCount":134},[],{"intervention":2160,"totalTrials":118,"cells":2169},{"EARLY_PHASE1":2170,"PHASE1":2172,"PHASE2":2174,"PHASE3":2180,"PHASE4":2182,"NA":2184},{"trials":2171,"activeCount":134},[],{"trials":2173,"activeCount":134},[],{"trials":2175,"activeCount":118,"soonestReadout":510},[2176],{"nctId":2153,"briefTitle":2154,"status":156,"phases":2177,"primaryCompletion":510,"completion":2156,"start":141,"enrollment":108,"conditions":2178,"interventions":2179},[90],[2158],[2144,2160,2161],{"trials":2181,"activeCount":134},[],{"trials":2183,"activeCount":134},[],{"trials":2185,"activeCount":134},[],{"intervention":2161,"totalTrials":118,"cells":2187},{"EARLY_PHASE1":2188,"PHASE1":2190,"PHASE2":2192,"PHASE3":2198,"PHASE4":2200,"NA":2202},{"trials":2189,"activeCount":134},[],{"trials":2191,"activeCount":134},[],{"trials":2193,"activeCount":118,"soonestReadout":510},[2194],{"nctId":2153,"briefTitle":2154,"status":156,"phases":2195,"primaryCompletion":510,"completion":2156,"start":141,"enrollment":108,"conditions":2196,"interventions":2197},[90],[2158],[2144,2160,2161],{"trials":2199,"activeCount":134},[],{"trials":2201,"activeCount":134},[],{"trials":2203,"activeCount":134},[],{"intervention":454,"totalTrials":118,"cells":2205},{"EARLY_PHASE1":2206,"PHASE1":2208,"PHASE2":2210,"PHASE3":2216,"PHASE4":2218,"NA":2220},{"trials":2207,"activeCount":134},[],{"trials":2209,"activeCount":134},[],{"trials":2211,"activeCount":118,"soonestReadout":447},[2212],{"nctId":444,"briefTitle":445,"status":156,"phases":2213,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":2214,"interventions":2215},[90],[15],[453,115,454,430,455,71,66,456],{"trials":2217,"activeCount":134},[],{"trials":2219,"activeCount":134},[],{"trials":2221,"activeCount":134},[],{"intervention":456,"totalTrials":118,"cells":2223},{"EARLY_PHASE1":2224,"PHASE1":2226,"PHASE2":2228,"PHASE3":2234,"PHASE4":2236,"NA":2238},{"trials":2225,"activeCount":134},[],{"trials":2227,"activeCount":134},[],{"trials":2229,"activeCount":118,"soonestReadout":447},[2230],{"nctId":444,"briefTitle":445,"status":156,"phases":2231,"primaryCompletion":447,"completion":448,"start":449,"enrollment":450,"conditions":2232,"interventions":2233},[90],[15],[453,115,454,430,455,71,66,456],{"trials":2235,"activeCount":134},[],{"trials":2237,"activeCount":134},[],{"trials":2239,"activeCount":134},[],{"intervention":2241,"totalTrials":118,"cells":2242},"Acetylsalicylic acid",{"EARLY_PHASE1":2243,"PHASE1":2245,"PHASE2":2247,"PHASE3":2259,"PHASE4":2261,"NA":2263},{"trials":2244,"activeCount":134},[],{"trials":2246,"activeCount":134},[],{"trials":2248,"activeCount":118,"soonestReadout":141},[2249],{"nctId":2250,"briefTitle":2251,"status":104,"phases":2252,"primaryCompletion":141,"completion":2253,"start":2254,"enrollment":2255,"conditions":2256,"interventions":2258},"NCT03480776","ASA in Prevention of Ovarian Cancer (STICs and STONEs)",[90],"2026-09-15","2018-07-24",117,[2257],"Ovarian Cancer Prevention",[2241],{"trials":2260,"activeCount":134},[],{"trials":2262,"activeCount":134},[],{"trials":2264,"activeCount":134},[],{"intervention":1268,"totalTrials":118,"cells":2266},{"EARLY_PHASE1":2267,"PHASE1":2269,"PHASE2":2275,"PHASE3":2277,"PHASE4":2279,"NA":2281},{"trials":2268,"activeCount":134},[],{"trials":2270,"activeCount":118,"soonestReadout":1260},[2271],{"nctId":1256,"briefTitle":1257,"status":1258,"phases":2272,"primaryCompletion":1260,"completion":1261,"start":1262,"enrollment":1176,"conditions":2273,"interventions":2274},[89],[1264,1265,1266],[1268,149,1269],{"trials":2276,"activeCount":134},[],{"trials":2278,"activeCount":134},[],{"trials":2280,"activeCount":134},[],{"trials":2282,"activeCount":134},[],{"intervention":1269,"totalTrials":118,"cells":2284},{"EARLY_PHASE1":2285,"PHASE1":2287,"PHASE2":2293,"PHASE3":2295,"PHASE4":2297,"NA":2299},{"trials":2286,"activeCount":134},[],{"trials":2288,"activeCount":118,"soonestReadout":1260},[2289],{"nctId":1256,"briefTitle":1257,"status":1258,"phases":2290,"primaryCompletion":1260,"completion":1261,"start":1262,"enrollment":1176,"conditions":2291,"interventions":2292},[89],[1264,1265,1266],[1268,149,1269],{"trials":2294,"activeCount":134},[],{"trials":2296,"activeCount":134},[],{"trials":2298,"activeCount":134},[],{"trials":2300,"activeCount":134},[],{"intervention":112,"totalTrials":118,"cells":2302},{"EARLY_PHASE1":2303,"PHASE1":2309,"PHASE2":2311,"PHASE3":2313,"PHASE4":2315,"NA":2317},{"trials":2304,"activeCount":118,"soonestReadout":106},[2305],{"nctId":102,"briefTitle":103,"status":104,"phases":2306,"primaryCompletion":106,"completion":106,"start":107,"enrollment":108,"conditions":2307,"interventions":2308},[88],[110],[112,113,114,115,96,76,116,117],{"trials":2310,"activeCount":134},[],{"trials":2312,"activeCount":134},[],{"trials":2314,"activeCount":134},[],{"trials":2316,"activeCount":134},[],{"trials":2318,"activeCount":134},[],{"intervention":114,"totalTrials":118,"cells":2320},{"EARLY_PHASE1":2321,"PHASE1":2327,"PHASE2":2329,"PHASE3":2331,"PHASE4":2333,"NA":2335},{"trials":2322,"activeCount":118,"soonestReadout":106},[2323],{"nctId":102,"briefTitle":103,"status":104,"phases":2324,"primaryCompletion":106,"completion":106,"start":107,"enrollment":108,"conditions":2325,"interventions":2326},[88],[110],[112,113,114,115,96,76,116,117],{"trials":2328,"activeCount":134},[],{"trials":2330,"activeCount":134},[],{"trials":2332,"activeCount":134},[],{"trials":2334,"activeCount":134},[],{"trials":2336,"activeCount":134},[],{"intervention":116,"totalTrials":118,"cells":2338},{"EARLY_PHASE1":2339,"PHASE1":2345,"PHASE2":2347,"PHASE3":2349,"PHASE4":2351,"NA":2353},{"trials":2340,"activeCount":118,"soonestReadout":106},[2341],{"nctId":102,"briefTitle":103,"status":104,"phases":2342,"primaryCompletion":106,"completion":106,"start":107,"enrollment":108,"conditions":2343,"interventions":2344},[88],[110],[112,113,114,115,96,76,116,117],{"trials":2346,"activeCount":134},[],{"trials":2348,"activeCount":134},[],{"trials":2350,"activeCount":134},[],{"trials":2352,"activeCount":134},[],{"trials":2354,"activeCount":134},[],{"intervention":117,"totalTrials":118,"cells":2356},{"EARLY_PHASE1":2357,"PHASE1":2363,"PHASE2":2365,"PHASE3":2367,"PHASE4":2369,"NA":2371},{"trials":2358,"activeCount":118,"soonestReadout":106},[2359],{"nctId":102,"briefTitle":103,"status":104,"phases":2360,"primaryCompletion":106,"completion":106,"start":107,"enrollment":108,"conditions":2361,"interventions":2362},[88],[110],[112,113,114,115,96,76,116,117],{"trials":2364,"activeCount":134},[],{"trials":2366,"activeCount":134},[],{"trials":2368,"activeCount":134},[],{"trials":2370,"activeCount":134},[],{"trials":2372,"activeCount":134},[],{"intervention":216,"totalTrials":25,"cells":2374},{"EARLY_PHASE1":2375,"PHASE1":2377,"PHASE2":2383,"PHASE3":2393,"PHASE4":2399,"NA":2401},{"trials":2376,"activeCount":134},[],{"trials":2378,"activeCount":134},[2379],{"nctId":329,"briefTitle":330,"status":124,"phases":2380,"primaryCompletion":332,"completion":333,"start":334,"enrollment":335,"conditions":2381,"interventions":2382},[89],[213],[338,242,339,216,76],{"trials":2384,"activeCount":134},[2385,2389],{"nctId":205,"briefTitle":206,"status":124,"phases":2386,"primaryCompletion":208,"completion":209,"start":210,"enrollment":211,"conditions":2387,"interventions":2388},[90],[213],[215,216,217,196],{"nctId":368,"briefTitle":369,"status":124,"phases":2390,"primaryCompletion":371,"completion":372,"start":373,"enrollment":374,"conditions":2391,"interventions":2392},[90],[376],[339,216,76,242],{"trials":2394,"activeCount":134},[2395],{"nctId":309,"briefTitle":310,"status":124,"phases":2396,"primaryCompletion":312,"completion":312,"start":313,"enrollment":314,"conditions":2397,"interventions":2398},[90,91],[316],[76,216,164],{"trials":2400,"activeCount":134},[],{"trials":2402,"activeCount":134},[],{"intervention":2404,"totalTrials":118,"cells":2405},"letrozole",{"EARLY_PHASE1":2406,"PHASE1":2408,"PHASE2":2410,"PHASE3":2412,"PHASE4":2424,"NA":2426},{"trials":2407,"activeCount":134},[],{"trials":2409,"activeCount":134},[],{"trials":2411,"activeCount":134},[],{"trials":2413,"activeCount":134},[2414],{"nctId":2415,"briefTitle":2416,"status":124,"phases":2417,"primaryCompletion":2418,"completion":2419,"start":2420,"enrollment":2421,"conditions":2422,"interventions":2423},"NCT00754845","Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy",[91],"2015-12-21","2017-04-19","2004-11-23",1918,[15],[2404],{"trials":2425,"activeCount":134},[],{"trials":2427,"activeCount":134},[],{"intervention":2429,"totalTrials":118,"cells":2430},"IMM-101",{"EARLY_PHASE1":2431,"PHASE1":2433,"PHASE2":2435,"PHASE3":2437,"PHASE4":2450,"NA":2452},{"trials":2432,"activeCount":134},[],{"trials":2434,"activeCount":134},[],{"trials":2436,"activeCount":134},[],{"trials":2438,"activeCount":134},[2439],{"nctId":2440,"briefTitle":2441,"status":124,"phases":2442,"primaryCompletion":2443,"completion":2444,"start":2445,"enrollment":2446,"conditions":2447,"interventions":2449},"NCT04442048","Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure",[91],"2024-05-07","2025-12-22","2020-10-01",195,[21,2448],"Covid-19",[2429],{"trials":2451,"activeCount":134},[],{"trials":2453,"activeCount":134},[],{"intervention":2455,"totalTrials":118,"cells":2456},"temozolomide",{"EARLY_PHASE1":2457,"PHASE1":2459,"PHASE2":2461,"PHASE3":2463,"PHASE4":2477,"NA":2479},{"trials":2458,"activeCount":134},[],{"trials":2460,"activeCount":134},[],{"trials":2462,"activeCount":134},[],{"trials":2464,"activeCount":134},[2465],{"nctId":2466,"briefTitle":2467,"status":124,"phases":2468,"primaryCompletion":2469,"completion":2470,"start":2471,"enrollment":2472,"conditions":2473,"interventions":2475},"NCT00482677","Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme",[91],"2016-03-01","2016-08-10","2007-11-14",562,[2474],"Brain and Central Nervous System Tumors",[2455,2476],"DNA methylation analysis",{"trials":2478,"activeCount":134},[],{"trials":2480,"activeCount":134},[],{"intervention":2476,"totalTrials":118,"cells":2482},{"EARLY_PHASE1":2483,"PHASE1":2485,"PHASE2":2487,"PHASE3":2489,"PHASE4":2495,"NA":2497},{"trials":2484,"activeCount":134},[],{"trials":2486,"activeCount":134},[],{"trials":2488,"activeCount":134},[],{"trials":2490,"activeCount":134},[2491],{"nctId":2466,"briefTitle":2467,"status":124,"phases":2492,"primaryCompletion":2469,"completion":2470,"start":2471,"enrollment":2472,"conditions":2493,"interventions":2494},[91],[2474],[2455,2476],{"trials":2496,"activeCount":134},[],{"trials":2498,"activeCount":134},[],{"intervention":2500,"totalTrials":118,"cells":2501},"metformin hydrochloride",{"EARLY_PHASE1":2502,"PHASE1":2504,"PHASE2":2506,"PHASE3":2508,"PHASE4":2520,"NA":2522},{"trials":2503,"activeCount":134},[],{"trials":2505,"activeCount":134},[],{"trials":2507,"activeCount":134},[],{"trials":2509,"activeCount":134},[2510],{"nctId":2511,"briefTitle":2512,"status":124,"phases":2513,"primaryCompletion":2514,"completion":2515,"start":2516,"enrollment":2517,"conditions":2518,"interventions":2519},"NCT01101438","A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer",[91],"2021-09-21","2023-08-18","2010-08-13",3649,[15],[2500],{"trials":2521,"activeCount":134},[],{"trials":2523,"activeCount":134},[],{"intervention":339,"totalTrials":33,"cells":2525},{"EARLY_PHASE1":2526,"PHASE1":2528,"PHASE2":2534,"PHASE3":2540,"PHASE4":2542,"NA":2544},{"trials":2527,"activeCount":134},[],{"trials":2529,"activeCount":134},[2530],{"nctId":329,"briefTitle":330,"status":124,"phases":2531,"primaryCompletion":332,"completion":333,"start":334,"enrollment":335,"conditions":2532,"interventions":2533},[89],[213],[338,242,339,216,76],{"trials":2535,"activeCount":134},[2536],{"nctId":368,"briefTitle":369,"status":124,"phases":2537,"primaryCompletion":371,"completion":372,"start":373,"enrollment":374,"conditions":2538,"interventions":2539},[90],[376],[339,216,76,242],{"trials":2541,"activeCount":134},[],{"trials":2543,"activeCount":134},[],{"trials":2545,"activeCount":134},[],{"intervention":924,"totalTrials":33,"cells":2547},{"EARLY_PHASE1":2548,"PHASE1":2550,"PHASE2":2552,"PHASE3":2562,"PHASE4":2564,"NA":2566},{"trials":2549,"activeCount":134},[],{"trials":2551,"activeCount":134},[],{"trials":2553,"activeCount":134},[2554,2558],{"nctId":914,"briefTitle":915,"status":124,"phases":2555,"primaryCompletion":917,"completion":918,"start":919,"enrollment":920,"conditions":2556,"interventions":2557},[90],[922],[115,924,56,862],{"nctId":1228,"briefTitle":1229,"status":124,"phases":2559,"primaryCompletion":1231,"completion":1232,"start":1233,"enrollment":1234,"conditions":2560,"interventions":2561},[90],[1236],[1238,338],{"trials":2563,"activeCount":134},[],{"trials":2565,"activeCount":134},[],{"trials":2567,"activeCount":134},[],{"intervention":840,"totalTrials":33,"cells":2569},{"EARLY_PHASE1":2570,"PHASE1":2572,"PHASE2":2578,"PHASE3":2584,"PHASE4":2586,"NA":2588},{"trials":2571,"activeCount":134},[],{"trials":2573,"activeCount":134},[2574],{"nctId":830,"briefTitle":831,"status":124,"phases":2575,"primaryCompletion":833,"completion":834,"start":835,"enrollment":836,"conditions":2576,"interventions":2577},[89],[838],[56,840],{"trials":2579,"activeCount":134},[2580],{"nctId":1099,"briefTitle":1100,"status":124,"phases":2581,"primaryCompletion":1102,"completion":1103,"start":1104,"enrollment":1105,"conditions":2582,"interventions":2583},[90],[1107],[453,115,1109,840,455],{"trials":2585,"activeCount":134},[],{"trials":2587,"activeCount":134},[],{"trials":2589,"activeCount":134},[],{"intervention":2591,"totalTrials":118,"cells":2592},"Dabrafenib",{"EARLY_PHASE1":2593,"PHASE1":2595,"PHASE2":2597,"PHASE3":2608,"PHASE4":2610,"NA":2612},{"trials":2594,"activeCount":134},[],{"trials":2596,"activeCount":134},[],{"trials":2598,"activeCount":134},[2599],{"nctId":2600,"briefTitle":2601,"status":274,"phases":2602,"primaryCompletion":2603,"completion":2603,"start":2604,"enrollment":97,"conditions":2605,"interventions":2606},"NCT02974803","Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases",[90],"2020-07-29","2018-02-09",[32,35],[2591,2607],"Trametinib",{"trials":2609,"activeCount":134},[],{"trials":2611,"activeCount":134},[],{"trials":2613,"activeCount":134},[],{"intervention":2607,"totalTrials":118,"cells":2615},{"EARLY_PHASE1":2616,"PHASE1":2618,"PHASE2":2620,"PHASE3":2626,"PHASE4":2628,"NA":2630},{"trials":2617,"activeCount":134},[],{"trials":2619,"activeCount":134},[],{"trials":2621,"activeCount":134},[2622],{"nctId":2600,"briefTitle":2601,"status":274,"phases":2623,"primaryCompletion":2603,"completion":2603,"start":2604,"enrollment":97,"conditions":2624,"interventions":2625},[90],[32,35],[2591,2607],{"trials":2627,"activeCount":134},[],{"trials":2629,"activeCount":134},[],{"trials":2631,"activeCount":134},[],{"intervention":1209,"totalTrials":118,"cells":2633},{"EARLY_PHASE1":2634,"PHASE1":2636,"PHASE2":2638,"PHASE3":2644,"PHASE4":2646,"NA":2648},{"trials":2635,"activeCount":134},[],{"trials":2637,"activeCount":134},[],{"trials":2639,"activeCount":134},[2640],{"nctId":1200,"briefTitle":1201,"status":124,"phases":2641,"primaryCompletion":1203,"completion":1204,"start":1205,"enrollment":1206,"conditions":2642,"interventions":2643},[90],[838],[338,1209],{"trials":2645,"activeCount":134},[],{"trials":2647,"activeCount":134},[],{"trials":2649,"activeCount":134},[],{"intervention":2651,"totalTrials":118,"cells":2652},"Docetaxel, Reolysin and Prednisone",{"EARLY_PHASE1":2653,"PHASE1":2655,"PHASE2":2657,"PHASE3":2670,"PHASE4":2672,"NA":2674},{"trials":2654,"activeCount":134},[],{"trials":2656,"activeCount":134},[],{"trials":2658,"activeCount":134},[2659],{"nctId":2660,"briefTitle":2661,"status":124,"phases":2662,"primaryCompletion":2663,"completion":2664,"start":2665,"enrollment":2666,"conditions":2667,"interventions":2668},"NCT01619813","Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer",[90],"2016-04-26","2016-05-20","2012-12-14",85,[18],[2651,2669],"Docetaxel and Prednisone",{"trials":2671,"activeCount":134},[],{"trials":2673,"activeCount":134},[],{"trials":2675,"activeCount":134},[],{"intervention":2669,"totalTrials":118,"cells":2677},{"EARLY_PHASE1":2678,"PHASE1":2680,"PHASE2":2682,"PHASE3":2688,"PHASE4":2690,"NA":2692},{"trials":2679,"activeCount":134},[],{"trials":2681,"activeCount":134},[],{"trials":2683,"activeCount":134},[2684],{"nctId":2660,"briefTitle":2661,"status":124,"phases":2685,"primaryCompletion":2663,"completion":2664,"start":2665,"enrollment":2666,"conditions":2686,"interventions":2687},[90],[18],[2651,2669],{"trials":2689,"activeCount":134},[],{"trials":2691,"activeCount":134},[],{"trials":2693,"activeCount":134},[],{"intervention":2695,"totalTrials":118,"cells":2696},"Palbociclib 100mg",{"EARLY_PHASE1":2697,"PHASE1":2699,"PHASE2":2701,"PHASE3":2714,"PHASE4":2716,"NA":2718},{"trials":2698,"activeCount":134},[],{"trials":2700,"activeCount":134},[],{"trials":2702,"activeCount":134},[2703],{"nctId":2704,"briefTitle":2705,"status":124,"phases":2706,"primaryCompletion":2707,"completion":2708,"start":2709,"enrollment":920,"conditions":2710,"interventions":2711},"NCT02630693","Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced\u002FMetastatic Breast Cancer",[90],"2018-08-15","2023-11-29","2016-04-08",[15],[2695,2712,2713],"Palbociclib 125mg","Fulvestrant or Tamoxifen or Aromatase Inhibitor",{"trials":2715,"activeCount":134},[],{"trials":2717,"activeCount":134},[],{"trials":2719,"activeCount":134},[],{"intervention":2712,"totalTrials":118,"cells":2721},{"EARLY_PHASE1":2722,"PHASE1":2724,"PHASE2":2726,"PHASE3":2732,"PHASE4":2734,"NA":2736},{"trials":2723,"activeCount":134},[],{"trials":2725,"activeCount":134},[],{"trials":2727,"activeCount":134},[2728],{"nctId":2704,"briefTitle":2705,"status":124,"phases":2729,"primaryCompletion":2707,"completion":2708,"start":2709,"enrollment":920,"conditions":2730,"interventions":2731},[90],[15],[2695,2712,2713],{"trials":2733,"activeCount":134},[],{"trials":2735,"activeCount":134},[],{"trials":2737,"activeCount":134},[],{"intervention":2713,"totalTrials":118,"cells":2739},{"EARLY_PHASE1":2740,"PHASE1":2742,"PHASE2":2744,"PHASE3":2750,"PHASE4":2752,"NA":2754},{"trials":2741,"activeCount":134},[],{"trials":2743,"activeCount":134},[],{"trials":2745,"activeCount":134},[2746],{"nctId":2704,"briefTitle":2705,"status":124,"phases":2747,"primaryCompletion":2707,"completion":2708,"start":2709,"enrollment":920,"conditions":2748,"interventions":2749},[90],[15],[2695,2712,2713],{"trials":2751,"activeCount":134},[],{"trials":2753,"activeCount":134},[],{"trials":2755,"activeCount":134},[],{"intervention":175,"totalTrials":118,"cells":2757},{"EARLY_PHASE1":2758,"PHASE1":2760,"PHASE2":2762,"PHASE3":2768,"PHASE4":2770,"NA":2772},{"trials":2759,"activeCount":134},[],{"trials":2761,"activeCount":134},[],{"trials":2763,"activeCount":134},[2764],{"nctId":166,"briefTitle":167,"status":124,"phases":2765,"primaryCompletion":169,"completion":170,"start":171,"enrollment":172,"conditions":2766,"interventions":2767},[90],[30],[175,149,96],{"trials":2769,"activeCount":134},[],{"trials":2771,"activeCount":134},[],{"trials":2773,"activeCount":134},[],{"intervention":215,"totalTrials":118,"cells":2775},{"EARLY_PHASE1":2776,"PHASE1":2778,"PHASE2":2780,"PHASE3":2786,"PHASE4":2788,"NA":2790},{"trials":2777,"activeCount":134},[],{"trials":2779,"activeCount":134},[],{"trials":2781,"activeCount":134},[2782],{"nctId":205,"briefTitle":206,"status":124,"phases":2783,"primaryCompletion":208,"completion":209,"start":210,"enrollment":211,"conditions":2784,"interventions":2785},[90],[213],[215,216,217,196],{"trials":2787,"activeCount":134},[],{"trials":2789,"activeCount":134},[],{"trials":2791,"activeCount":134},[],{"intervention":217,"totalTrials":118,"cells":2793},{"EARLY_PHASE1":2794,"PHASE1":2796,"PHASE2":2798,"PHASE3":2804,"PHASE4":2806,"NA":2808},{"trials":2795,"activeCount":134},[],{"trials":2797,"activeCount":134},[],{"trials":2799,"activeCount":134},[2800],{"nctId":205,"briefTitle":206,"status":124,"phases":2801,"primaryCompletion":208,"completion":209,"start":210,"enrollment":211,"conditions":2802,"interventions":2803},[90],[213],[215,216,217,196],{"trials":2805,"activeCount":134},[],{"trials":2807,"activeCount":134},[],{"trials":2809,"activeCount":134},[],{"intervention":2811,"totalTrials":118,"cells":2812},"Folfox plus Bevacizumab and reolysin",{"EARLY_PHASE1":2813,"PHASE1":2815,"PHASE2":2817,"PHASE3":2830,"PHASE4":2832,"NA":2834},{"trials":2814,"activeCount":134},[],{"trials":2816,"activeCount":134},[],{"trials":2818,"activeCount":134},[2819],{"nctId":2820,"briefTitle":2821,"status":124,"phases":2822,"primaryCompletion":2823,"completion":2824,"start":2825,"enrollment":2826,"conditions":2827,"interventions":2828},"NCT01622543","Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer",[90],"2017-01-18","2018-09-12","2012-10-26",109,[24],[2811,2829],"Folfox plus Bevacizumab",{"trials":2831,"activeCount":134},[],{"trials":2833,"activeCount":134},[],{"trials":2835,"activeCount":134},[],{"intervention":2829,"totalTrials":118,"cells":2837},{"EARLY_PHASE1":2838,"PHASE1":2840,"PHASE2":2842,"PHASE3":2848,"PHASE4":2850,"NA":2852},{"trials":2839,"activeCount":134},[],{"trials":2841,"activeCount":134},[],{"trials":2843,"activeCount":134},[2844],{"nctId":2820,"briefTitle":2821,"status":124,"phases":2845,"primaryCompletion":2823,"completion":2824,"start":2825,"enrollment":2826,"conditions":2846,"interventions":2847},[90],[24],[2811,2829],{"trials":2849,"activeCount":134},[],{"trials":2851,"activeCount":134},[],{"trials":2853,"activeCount":134},[],{"intervention":2855,"totalTrials":118,"cells":2856},"Folfox Protocol",{"EARLY_PHASE1":2857,"PHASE1":2859,"PHASE2":2861,"PHASE3":2873,"PHASE4":2875,"NA":2877},{"trials":2858,"activeCount":134},[],{"trials":2860,"activeCount":134},[],{"trials":2862,"activeCount":134},[2863],{"nctId":2864,"briefTitle":2865,"status":124,"phases":2866,"primaryCompletion":2867,"completion":487,"start":2868,"enrollment":2869,"conditions":2870,"interventions":2871},"NCT03259035","NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer",[90],"2024-04-08","2018-06-29",58,[637],[2855,2872],"Capox",{"trials":2874,"activeCount":134},[],{"trials":2876,"activeCount":134},[],{"trials":2878,"activeCount":134},[],{"intervention":2872,"totalTrials":118,"cells":2880},{"EARLY_PHASE1":2881,"PHASE1":2883,"PHASE2":2885,"PHASE3":2891,"PHASE4":2893,"NA":2895},{"trials":2882,"activeCount":134},[],{"trials":2884,"activeCount":134},[],{"trials":2886,"activeCount":134},[2887],{"nctId":2864,"briefTitle":2865,"status":124,"phases":2888,"primaryCompletion":2867,"completion":487,"start":2868,"enrollment":2869,"conditions":2889,"interventions":2890},[90],[637],[2855,2872],{"trials":2892,"activeCount":134},[],{"trials":2894,"activeCount":134},[],{"trials":2896,"activeCount":134},[],{"intervention":1109,"totalTrials":118,"cells":2898},{"EARLY_PHASE1":2899,"PHASE1":2901,"PHASE2":2903,"PHASE3":2909,"PHASE4":2911,"NA":2913},{"trials":2900,"activeCount":134},[],{"trials":2902,"activeCount":134},[],{"trials":2904,"activeCount":134},[2905],{"nctId":1099,"briefTitle":1100,"status":124,"phases":2906,"primaryCompletion":1102,"completion":1103,"start":1104,"enrollment":1105,"conditions":2907,"interventions":2908},[90],[1107],[453,115,1109,840,455],{"trials":2910,"activeCount":134},[],{"trials":2912,"activeCount":134},[],{"trials":2914,"activeCount":134},[],{"intervention":2916,"totalTrials":118,"cells":2917},"BKM120",{"EARLY_PHASE1":2918,"PHASE1":2920,"PHASE2":2922,"PHASE3":2935,"PHASE4":2937,"NA":2939},{"trials":2919,"activeCount":134},[],{"trials":2921,"activeCount":134},[],{"trials":2923,"activeCount":134},[2924],{"nctId":2925,"briefTitle":2926,"status":124,"phases":2927,"primaryCompletion":2928,"completion":834,"start":2929,"enrollment":2930,"conditions":2931,"interventions":2933},"NCT01591421","P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic\u002FAdvanced RAS-Wild Type Colorectal Cancer.",[89,90],"2015-09-30","2012-09-06",22,[2932],"Metastatic Colorectal Cancer",[2916,2934],"Panitumumab",{"trials":2936,"activeCount":134},[],{"trials":2938,"activeCount":134},[],{"trials":2940,"activeCount":134},[],{"intervention":2934,"totalTrials":118,"cells":2942},{"EARLY_PHASE1":2943,"PHASE1":2945,"PHASE2":2947,"PHASE3":2953,"PHASE4":2955,"NA":2957},{"trials":2944,"activeCount":134},[],{"trials":2946,"activeCount":134},[],{"trials":2948,"activeCount":134},[2949],{"nctId":2925,"briefTitle":2926,"status":124,"phases":2950,"primaryCompletion":2928,"completion":834,"start":2929,"enrollment":2930,"conditions":2951,"interventions":2952},[89,90],[2932],[2916,2934],{"trials":2954,"activeCount":134},[],{"trials":2956,"activeCount":134},[],{"trials":2958,"activeCount":134},[],{"intervention":2960,"totalTrials":118,"cells":2961},"Nivolumab",{"EARLY_PHASE1":2962,"PHASE1":2964,"PHASE2":2966,"PHASE3":2978,"PHASE4":2980,"NA":2982},{"trials":2963,"activeCount":134},[],{"trials":2965,"activeCount":134},[],{"trials":2967,"activeCount":134},[2968],{"nctId":2969,"briefTitle":2970,"status":274,"phases":2971,"primaryCompletion":2972,"completion":2973,"start":2974,"enrollment":25,"conditions":2975,"interventions":2976},"NCT03461952","Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)",[90],"2021-06-01","2022-02-09","2019-03-11",[1324],[2960,2977],"Ipilimumab",{"trials":2979,"activeCount":134},[],{"trials":2981,"activeCount":134},[],{"trials":2983,"activeCount":134},[],{"intervention":2977,"totalTrials":118,"cells":2985},{"EARLY_PHASE1":2986,"PHASE1":2988,"PHASE2":2990,"PHASE3":2996,"PHASE4":2998,"NA":3000},{"trials":2987,"activeCount":134},[],{"trials":2989,"activeCount":134},[],{"trials":2991,"activeCount":134},[2992],{"nctId":2969,"briefTitle":2970,"status":274,"phases":2993,"primaryCompletion":2972,"completion":2973,"start":2974,"enrollment":25,"conditions":2994,"interventions":2995},[90],[1324],[2960,2977],{"trials":2997,"activeCount":134},[],{"trials":2999,"activeCount":134},[],{"trials":3001,"activeCount":134},[],{"intervention":295,"totalTrials":118,"cells":3003},{"EARLY_PHASE1":3004,"PHASE1":3006,"PHASE2":3008,"PHASE3":3014,"PHASE4":3016,"NA":3018},{"trials":3005,"activeCount":134},[],{"trials":3007,"activeCount":134},[],{"trials":3009,"activeCount":134},[3010],{"nctId":287,"briefTitle":288,"status":289,"phases":3011,"primaryCompletion":291,"completion":291,"start":291,"enrollment":134,"conditions":3012,"interventions":3013},[90],[293],[164,295],{"trials":3015,"activeCount":134},[],{"trials":3017,"activeCount":134},[],{"trials":3019,"activeCount":134},[],{"intervention":3021,"totalTrials":118,"cells":3022},"Buparlisib",{"EARLY_PHASE1":3023,"PHASE1":3025,"PHASE2":3027,"PHASE3":3039,"PHASE4":3041,"NA":3043},{"trials":3024,"activeCount":134},[],{"trials":3026,"activeCount":134},[],{"trials":3028,"activeCount":134},[3029],{"nctId":3030,"briefTitle":3031,"status":124,"phases":3032,"primaryCompletion":3033,"completion":3034,"start":3035,"enrollment":3036,"conditions":3037,"interventions":3038},"NCT02340780","Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia",[90],"2018-11-21","2020-04-28","2015-04-27",14,[27],[3021],{"trials":3040,"activeCount":134},[],{"trials":3042,"activeCount":134},[],{"trials":3044,"activeCount":134},[],{"intervention":1306,"totalTrials":118,"cells":3046},{"EARLY_PHASE1":3047,"PHASE1":3049,"PHASE2":3055,"PHASE3":3057,"PHASE4":3059,"NA":3061},{"trials":3048,"activeCount":134},[],{"trials":3050,"activeCount":134},[3051],{"nctId":1294,"briefTitle":1295,"status":124,"phases":3052,"primaryCompletion":1297,"completion":1298,"start":1299,"enrollment":19,"conditions":3053,"interventions":3054},[89],[1301,1302,1303,1304],[1306,1287],{"trials":3056,"activeCount":134},[],{"trials":3058,"activeCount":134},[],{"trials":3060,"activeCount":134},[],{"trials":3062,"activeCount":134},[],{"intervention":3064,"totalTrials":118,"cells":3065},"IPH2201",{"EARLY_PHASE1":3066,"PHASE1":3068,"PHASE2":3080,"PHASE3":3082,"PHASE4":3084,"NA":3086},{"trials":3067,"activeCount":134},[],{"trials":3069,"activeCount":134},[3070],{"nctId":3071,"briefTitle":3072,"status":124,"phases":3073,"primaryCompletion":3074,"completion":834,"start":3075,"enrollment":3076,"conditions":3077,"interventions":3079},"NCT02459301","A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies",[89],"2017-11-15","2015-09-17",59,[3078],"Gynecologic Cancer",[3064],{"trials":3081,"activeCount":134},[],{"trials":3083,"activeCount":134},[],{"trials":3085,"activeCount":134},[],{"trials":3087,"activeCount":134},[],{"intervention":133,"totalTrials":118,"cells":3089},{"EARLY_PHASE1":3090,"PHASE1":3092,"PHASE2":3098,"PHASE3":3100,"PHASE4":3102,"NA":3104},{"trials":3091,"activeCount":134},[],{"trials":3093,"activeCount":134},[3094],{"nctId":122,"briefTitle":123,"status":124,"phases":3095,"primaryCompletion":126,"completion":127,"start":128,"enrollment":9,"conditions":3096,"interventions":3097},[89],[130,131],[115,96,76,133],{"trials":3099,"activeCount":134},[],{"trials":3101,"activeCount":134},[],{"trials":3103,"activeCount":134},[],{"trials":3105,"activeCount":134},[],{"intervention":3107,"totalTrials":118,"cells":3108},"AZD2014",{"EARLY_PHASE1":3109,"PHASE1":3111,"PHASE2":3122,"PHASE3":3124,"PHASE4":3126,"NA":3128},{"trials":3110,"activeCount":134},[],{"trials":3112,"activeCount":134},[3113],{"nctId":3114,"briefTitle":3115,"status":124,"phases":3116,"primaryCompletion":276,"completion":3117,"start":3118,"enrollment":836,"conditions":3119,"interventions":3121},"NCT02619864","mTORC1\u002FmTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme",[89],"2020-02-25","2016-12-22",[3120],"Glioblastoma Multiforme",[3107],{"trials":3123,"activeCount":134},[],{"trials":3125,"activeCount":134},[],{"trials":3127,"activeCount":134},[],{"trials":3129,"activeCount":134},[],{"intervention":3131,"totalTrials":118,"cells":3132},"CX5461",{"EARLY_PHASE1":3133,"PHASE1":3135,"PHASE2":3147,"PHASE3":3149,"PHASE4":3151,"NA":3153},{"trials":3134,"activeCount":134},[],{"trials":3136,"activeCount":134},[3137],{"nctId":3138,"briefTitle":3139,"status":124,"phases":3140,"primaryCompletion":3141,"completion":3142,"start":3143,"enrollment":3144,"conditions":3145,"interventions":3146},"NCT02719977","A Phase I Study of CX5461",[89],"2020-01-30","2023-01-18","2016-06-13",41,[21],[3131],{"trials":3148,"activeCount":134},[],{"trials":3150,"activeCount":134},[],{"trials":3152,"activeCount":134},[],{"trials":3154,"activeCount":134},[]]